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ABSTRACT OF THE DISSERTATION
INVESTIGATION OF DNA DAMAGE AND GENOMIC ORGANIZATION IN THE
CELLULAR RESPONSE TO PLATINUM CHEMOTHERAPY

by
Abdulhadi Mohammed S Abdulwahed
Florida International University, 2020
Miami, Florida
Professor Marcus S. Cooke, Co-Major Professor
Professor Deodutta Roy, Co-Major Professor
Ovarian cancer (OC) is the primary reason for gynecological cancer-related deaths among
women. This cancer rarely has specific symptoms making early detection challenging.
Platinum compounds have been used as the first-line treatment for OC. However, OC
patients often develop chemoresistance to current platinum/taxane chemotherapy regimens
upon recurrence, leaving patients with no alternative treatment options. The purpose of this
thesis was to investigate the molecular basis of chemoresistance in OC by analyzing the
damage of DNA response and gene positioning after treatment exposure. A modified comet
assay was used to measure interstrand cross-link (ICL) formation and repair in
chemoresistant (CR) (SKOV-3) and chemosensitive (CS) (A2780/OCIP5X) ovarian cancer
cell lines. Although the peak of ICL formation for the three cell lines was at 12 h, a
significant attenuation of ICL formation in SKOV-3 was observed, compared to the
chemosensitive lines. Furthermore, ICL levels in SKOV-3 did not return baseline, in
contrast to the chemosensitive cell lines. We further investigated the basis of this
differential DNA damage response by examining the potential role of nuclear organization,
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via the comparison of damage induction in nucleoid bodies versus intact cells. The results
demonstrated the same rank order of dose-response in nucleoid bodies as observed in intact
cells, with chemoresistant cells being considerably more resistant to damage formation, at
all doses of cisplatin. When studying gene positioning, we hypothesized that there is a
difference in the organization of chromatin in CS and CR ovarian cancer cell lines. The
organization of seventeen genes was tested in CR and CS cells. Non-random organization
was observed for the majority of genes (47.06%). BRAF and AKT3 were randomly
organized in CS and non-randomly organized in CR. A significantly increased copy
number was observed in the CR cell line compared to the CS in the majority of the studied
genes. The overall data provide the basis for further investigation to improve our
understanding of the differential DNA damage response and gene positioning associated
with chemosensitive and chemoresistant ovarian cells. Elucidating the mechanisms of
chemoresistance may ultimately lead to novel therapeutic interventions that may
resensitize or prevent the development of chemoresistance.
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CHAPTER 1
INTRODUCTION

1

1. Introduction
1.0 Ovarian cancer and chemotherapy
The leading cause of women's mortality due to a malignancy of the female
reproductive system is caused by ovarian cancer. Ovarian cancer is ranked fifth in terms of
deaths amongst women, compared to the other types of cancer [1]. Most women who have
ovarian cancer usually experience severe symptoms during the last stages of ovarian
cancer. It is during the late stages of the disease that most women are diagnosed. This is
because many women are usually asymptomatic or have non-specific symptoms during the
early stages of ovarian cancer, where the disease can be cured more effectively [2]. When
it comes to managing early and advanced phases of ovarian cancer, the most commonly
used treatment techniques include cytoreductive surgery to remove the tumor, followed by
chemotherapy. The chemotherapy involves a taxane doublet and a platinum compound [3,
4, 5]. Following surgery and chemotherapy, the initial response rate ranges from 70% to
80%; however, disease relapse occurs in less than two years in many patients.
Unfortunately, some patients' chemoresistance makes it challenging to manage the
condition when it recurs [6,7]. Therefore, this chapter will focus on reviewing ovarian
cancer in general and the factors involved in the chemoresistance.
1.1 Symptoms and treatments of ovarian cancer
Ovarian cancer, in its early stage, is generally asymptomatic and is often
incidentally diagnosed. It shows nonspecific symptoms, which are generally noticeable
only when the cancer advances and spreads throughout the abdominal cavity. Symptoms
associated with malignancy include abdominal fullness, vague pain in the abdomen, early
satiety, bowel habit changes, bloating, and dyspepsia. If identified in the early stages, the
2

five-year survival rate of ovarian cancer is up to 90 %, whereas, in the case of late-stage,
the five-year survival rate is less than 30 % [8]. Currently, ultrasound and CA-125 (Cancer
Antigen 125) are used as detection strategies. However, these techniques have
shortcomings, which results in a lack of a robust and sensitive screening test for the disease
1.1.1 Treatment options
At present, the first-line treatment option for most ovarian cancers is surgery. The
decision to which surgery should be carried out depends on the spread of cancer and the
patient's general health. If the patient is diagnosed at early stages, it is possible to treat
cancer without removing women's uterus and ovaries for certain types of tumors.
Another option is chemotherapy, in which cytotoxic drugs are used to treat cancer.
The chemotherapy acts at a systemic level where the drugs enter into the bloodstream and
reach more or less all the body regions. This method can help eliminate malignant cells
that may have been left after surgery, for metastasized cancers, or for shrinking oversized
cancer to facilitate surgery. In most cases of chemotherapy, drugs are injected into a vein
(IV) or given orally. In other cases, the intraperitoneal (IP) chemotherapy method is used.
In this method, drugs are injected directly into the abdominal cavity through a catheter.
Usually, two different types of drugs are used together in the chemotherapy
treatment of ovarian cancer. The combination drug approach used to treat ovarian cancer
is more efficacious than utilizing a single-drug approach. Generally, the combination
approach includes two kinds of chemotherapy drugs involving a platinum compound and
taxane (a chemotherapeutic agent that blocks cell growth by stopping cell division).
Common platinum compounds used for treatment include cisplatin or carboplatin, whereas
paclitaxel (Taxol) or docetaxel (Taxotere) are generally used as the taxane. These
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treatments are generally given every three to four weeks into a vein. Depending on the type
and stage of ovarian cancer, a typical chemotherapy course involves the treatment of 3 to
6 cycles [8-9].
1.2 Platinum compounds
In the oncology field, there has been an increased focus on platinum compounds
such as cisplatin, carboplatin, and oxaliplatin for the past forty years (Table 1.1.1). They
play a vital role in treating cervical cancer, lung cancer, colorectal cancer, head and neck
cancer, and bladder cancer [10]. They are most effective against germ cell tumors and
epithelial ovarian cancer. Cisplatin is often used as a first-line treatment option when it
comes to managing cancerous cells. However, in the matter of the treatment of colorectal
cancer, oxaliplatin is more effective than cisplatin. The key mechanism to their activity is
the formation of DNA crosslinks, which interrupts the proper functioning of cellular DNA,
which subsequently induces apoptosis [11].

4

Table 1.1.1 Chemical structures of the platinum family of chemotherapeutic agents

Platinum
compound

Formula

Cisplatin

Pt(NH3)2Cl2

Carboplatin

C6H12N2O4Pt

Oxaliplatin

C8H14N2O4Pt

Structure

5

1.2.1 Cisplatin
Cisplatin is considered as a chemotherapeutic agent for a variety of different types
of tumors. It is the oldest member of the platinum family whose toxicity profile is wellrecognized, including renal dysfunction, emesis, neurotoxicity, and ototoxicity [12]. DNA
is the primary cellular target for cisplatin, however it can also can react with protein.
Cisplatin can bind with the N7 position in purine bases in DNA once cisplatin molecular
enter a cell and become active by displacing the chloride ligands with water molecules;
different adducts then will be formed (Figure 1.1.1) [13]. The formation of these bulky
DNA adducts alters DNA's conformation, which disturbs replication and inhibits DNA
synthesis. If the DNA damage were not sufficient to cause cells to undergo apoptosis, the
cisplatin lesions would arrest cells in the G2 and S phases of the cell cycle. This
phenomenon exerts a cytoprotective effect by either preventing potentially abnormal or
abortive mitoses or allowing the DNA repair mechanisms to re-establish the integrity of
the DNA [14]. However, if the DNA repair systems fail to repair the damage induced, cells
will typically undergo apoptosis.

6

Figure 1.1.1 Different kinds of cisplatin DNA adducts. A) 1,2-d(GpG) intrastrand
cisplatin. B) 1,2-d(GpA) intrastrand cisplatin crosslinks. C) d(G-G) interstrand cisplatin
crosslinks. D) DNA-cisplatin-protein adducts, which known as a monoadduct.
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1.2.2 Carboplatin
Carboplatin is typically used for chemotherapy of neck, lung, and ovaries. The drug
has a structure that is composed of a ligand of bidentate dicarboxylate, unlike cisplatin
which has ligands of two chlorides in the same position. The carboplatin structure can
reduce reactivity and minimize binding mechanisms to DNA even though the crosslinks
are the same as those formed while using cisplatin at a similar dose [15].
1.2.3 Oxaliplatin
The mode of action of oxaliplatin is the same as that seen in cisplatin and
carboplatin. However, the oxaliplatin–DNA complex cannot be recognized by the enzymes
involved in the repair of DNA mismatch. This is because the complex has a larger size
compared to cisplatin (Table 1.1). This drug is frequently used in the management of
gastric, pancreatic, and colorectal cancers.
Platinum-based chemotherapeutic agents are used to treat many types of cancer.
However, in most malignancies, the efficacy of a platinum chemotherapeutic agent is
limited by resistance development. Although various factors are known to contribute to
platinum resistance, alterations of DNA repair processes are known to be significant in
mediating the resistance. Recent studies have provided an in-depth understanding of the
molecular mechanisms of pathways involved in DNA repair and their influence on
chemotherapy [16].
1.3 The Molecular mechanism of chemoresistance in ovarian cancer
Mutations that occur in an individual's genes lead to drug resistance in many cases,
which has resulted in a multifactorial challenge. The abnormal balance between numerous
pathways in the cells and the undermining of tumor suppressors, which participate in
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regulating apoptosis, enhance drug detoxification and clearance, and decrease the drug's
efficacy due to increased DNA repair, are some of the problems caused by mutations [17].
Here are the key factors that may play roles in chemoresistance in ovarian cancer.
1.3.1 Decreased of intracellular drug accumulation
Platinum-resistant cells, in an invitro study , showed a reduction in cellular uptake
with cisplatin chemotherapy [18]. The decreased accumulation of cisplatin is attributed to
either drug efflux increases or drug uptake inhibition. At times, both factors may contribute
to decreased accumulation of cisplatin in chemoresistant cells [18].
Through the processes of facilitated transport and passive diffusion, accumulation
of cisplatin and other compounds related to it occur in the cells. The influx of cisplatin and
its analogs are controlled by the copper transporter-1 (CTR1). A study showed that the
deletion of the CTR1 gene resulted in increased resistance to cisplatin and decreased
accumulation of the drug in different cell lines (cisplatin-sensitive and cisplatin-resistant
mammalian cells) that comprised ovarian cancer [19].
1.3.2 Deactivation of intracellular cisplatin
Glutathione is an intracellular thiol found in large amounts in cells and plays a vital
role in the detoxification of cisplatin and its related compounds and removing many other
toxins found in cells. The compound performs this function together with other elements
such as proteins rich in cysteine, metallothionein, and methionine. However, an enzyme
known as GSH-S-transferase π can effectively transform intracellular cisplatin into inactive
conjugates of cisplatin-thiol. The enzymes γ-glutamylcysteine synthetase and GSTπ play a
role in making some cell lines resistant such as those in the lung, cervical, and ovarian
cancer [20, 21, 22].
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1.3.3 Increased DNA repair
The presence of cisplatin-DNA adducts is responsible for cisplatin cytotoxicity. A
balance between the repair of DNA and DNA damage determines the survival or death of
cancerous cells after using the cisplatin drug during the management period. Many defects
in the DNA can be successfully repaired by the DNA repair mechanisms, including
eliminating platinum-DNA adducts [23].
Cisplatin is a chemotherapeutic agent that induces DNA damage, however, it is
less effective with the involvement of the DNA repair systems. Section 1.4 explores details
regarding the types of DNA repair systems involved in repairing the damaged DNA
following cisplatin treatment.
1.4 DNA Repair systems
Several repair systems are involved in the repair process following the cisplatininduced DNA damage. The major repair systems involved in the repair of the cisplatinDNA adducts are nucleotide excision repair (NER), mismatch repair (MMR), homologous
recombination (HR), nonhomologous end joining (NHEJ), and base excision repair (BER)
[24]. From several studies, the association of the cisplatin chemoresistance and the
mentioned DNA repair pathways are reviewed in this section.
Moreover, recent studies indicated that Fanconi anemia pathway (FA) plays a role
in increasing the sensitivity to interstrand cross-links (ICLs) [25]. Section 1.4.5 describes
some recent evidence indicating the relationship between the FA pathway (to repair ICLs)
and the chemoresistance.
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1.4.1 Nucleotide excision repair
NER has a role in the repair of cisplatin-DNA adducts. There are two pathways in
this repair system, transcription-coupled repair (TC-NER) and global genome repair (GGNER), which are involved in recognizing and repairing DNA damage. Different repair
proteins are involved in each pathway, explained in detail elsewhere [26].
There are several steps in the NER pathway; upon detecting bulky adducts in DNA,
a patch consisting of approximately 30 nucleobases is removed by two distinct complexes
(one 5' to the damage and one 3' to the damage). A polymerase then fills the gap using the
undamaged strand as a template, thereby relegating the DNA backbone by DNA ligase IV
[26]. Figure 1.1.2 illustrates the main steps of the NER pathway, repairing bulky DNA
lesions.
ICLs are one of the lesions created by cisplatin. Processing and removing ICLs by
DNA repair proteins include NER, HR, and FA pathways. NER has been reported to be
the primary repair pathway for removing the cisplatin lesions [27, 28]. Cisplatin can
activate NER proteins because it can bind to the DNA helix and make adducts that damage
the DNA [29].
Numerous studies showed the association of the NER pathway and cisplatin
resistance. The XPF and ERCC1 are associated with cisplatin chemoresistance for several
types of cancer [26-30]. Moreover, evidence showed that ERCC1-XPF is involved in
repairing ICL and decrease the DNA backbone in the region 5' in the NER pathway [31,
32]. However, it also plays an imperative role in regulating sensitivity to severity of
cisplatin [31, 32]
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Another primary lesion caused by DNA damage induced by cisplatin is the
intrastrand crosslink, which is often repaired by NER. Mutations in NER can result in the
rare autosomal recessive condition xeroderma pigmentosum. This condition causes
affected individuals to be highly sensitive to UV light and have a significantly increased
risk of developing skin cancer. Cells from these patients have also been shown to exhibit
sensitivity to cisplatin [33].
Moreover, the reduction of ERCC1 and XPA protein production in testis tumor
cells resulted in increased sensitivity in these cells to cisplatin-induced DNA adducts [34,
35]. In many studies, the overexpression of XPA and ERCC1 was linked to cisplatin
resistance [34-36]. For instance, in a study of ovarian cancer cell lines, alternative splicing
occurred, which was influenced by the presence of ERCC1 exon VIII [36, 37]. Even though
the excision never interfered with the amount of ERCC1, the repair function that occurs
after excision was significantly reduced.
Moreover, epigenetic factors such as ERCC1 hypermethylation increase cisplatin's
sensitivity because this is inversely correlated with the amount of ERCC1 mRNA [37]. In
addition, this study has also explained that the binding factor of ERCC1 is needed to repair
DNA damage induced by cisplatin [38]. The sensitivity of cisplatin was further enhanced
through a double knockdown of a complex formed between ERCC1 and XPF of lung
cancer cells [38].
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Figure 1.1.2 Overview of the NER pathway. Bulky DNA lesions like cyclobutane
pyrimidine dimers (CPDs), 6-4 photoproducts (6-4 PPs) or ICLs are removed by NER.
Subsequent steps are shared and include local duplex unwinding, DNA strand dual
incision, DNA synthesis, and ligation.
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1.4.2 Mismatch repair
MMR is a strand-specific, highly conserved repair pathway that is initiated with the
recognition of DNA damage and follows a stepwise process [39, 40]. Unmatched or
mismatched DNA base pairs or insertion-deletion loops are recognized by MMR proteins
called as Mut proteins, which initiate the assembly of proteins that excise the affected
region. Afterward, the excised region is resynthesized by DNA polymerase using the
unaffected template strand by DNA polymerase. Figure 1.1.3 shows a schematic
illustration of the MMR pathway; proteins involved in MMR and main steps were reviewed
in detail elsewhere [41]
Deficiencies in the MMR process can result in the accumulation of unrepaired
regions of DNA, which can result in microsatellite instability [42]. The accumulation
happens due to the replication of unrepaired base pair mismatches during DNA replication,
and repeats are formed due to the slippage of the replication machinery in these areas.
Defects in MMR may occur through epigenetic silencing of an essential MMR gene
[42, 43, 44] or be inherited [45]. It has been indicated that in several types of cancer, such
as ovarian, gastric, and colorectal carcinoma, the epigenetic silencing of MMR has been
shown to happen by hypermethylation of hMLH1 promoter [46, 47, 48]. Moreover, a study
investigated the Mut proteins involved in the MMR pathway showed an increase in
cisplatin effectivity in MSH2/MSH6-dependent manner, which lead to apoptosis [49]. In
comparison, MLH1-deficient cells showed less response to cisplatin than MLH1-proficient
cells. Moreover, cisplatin induces cell death was associated with proteolysis of MLH1[50].
These facts were associated with the destabilization of XIAP, which prompts caspase
activation [51]. Unlike the NER pathway, there is an association with faulty MMR and
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chemoresistance of carboplatin and cisplatin resistance [51, 52, 53] as a result of apoptosis
activation through MMR proteins [54, 55].

15

Figure 1.1.3 Schematic representation of MMR pathway. Mismatched nucleobase is
recognised in the new strand and removed. In the next step the mismatch base replaced
with the correct nucleotides. The DNA ligase will be used to seal the gap in the DNA as a
final step.
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1.4.3 Homologous recombination
HR pathway is involved in the repair process of double-strand breaks (DSBs) and
ICLs. Different proteins are involved in the HR process, which starts with recognizing the
strand breaks. Afterword, BRCA1 mediates the MRN complex, which was activated by
ATM kinase through phosphorylation. Eventually, resection of the complex takes place at
the 3’ends of the DSB, unzipping the DNA single-strand to facilitate the invasion of the
sister chromosome by the destroyed 3’ end where RAD51 and BRCA2 are involved. The
extension of the destroyed 3’ is then achieved by DNA polymerase, which utilizes the
complementary strand (Figure 1.1.4) [56, 57]. The process and the involved proteins in the
HR pathway were reviewed in detail elsewhere [58]
HR pathway plays a role in repairing ICLs induced by cisplatin; different studies
indicated the relationship between the HR pathway and cisplatin. For instance, the
deflection in BRCA2 in cancer cells enhances the chemosensitivity to cisplatin [59].
BRCA2 is an essential factor in the HR pathway during the conjunction step with Rad51
[60]. Therefore, ovarian carcinoma patients with BRCA1/2-mutation respond to platinum
chemotherapy, which improves their survival [61]. However, different trials have also
shown that mutation in these two genes leads to cisplatin resistance [62,63]
1.4.4 Nonhomologous end-joining
NHEJ is another pathway to repair DSBs, which can be induced by different
genotoxic agents such as anthracyclines, topoisomerase toxins, and bleomycin. The NHEJ
pathway process includes different types of proteins, which been described in detail
elsewhere [64]. Following the DSB occurred, the catalytic component and regulatory
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component make up the regulatory subunit (the Ku70/Ku80 heterodimer) and the DNAdependent protein kinase (DNA-PKcs) enzyme.
DNA PKcs is composed of threonine or serine kinase from the category of
phosphatidyl inositol-3 kinase. The complex's regulatory subunit shows no dependence on
the sequence when it binds to the DNA strand and double-stranded ends. These ends are
essential in activating and promoting the subunit made of the catalytic component. Also,
during the NHEJ pathway, extra proteins such as DNA ligase IV and Artemis are used.
Considering that there is usually no dependence on the complementary strand, insertion,
and deletion of nucleotides occur during DNA duplexes fusion [65, 66].
Several investigations showed the relationship between the NHEJ pathway and
cisplatin. It was demonstrated that cisplatin leads to increased cancer cells' sensitivity to
ionizing radiation via inhibition of NHEJ [67]. Moreover, cancer cells become sensitive to
cisplatin inducing ICL following DNA-PK inhibition, which is a factor involved in DSBs
repairing via its Ku subunits. [68]
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Figure 1.1.4 Overview of the HR and NHEJ pathway. After detection of the DSB, the
5′ strands are resected, producing long 3′ single-stranded DNA tails that then serve as a
substrate for assembly of a Rad51 nucleoprotein filament. Branch migration of this joint
DNA molecule, DNA synthesis, ligation, and resolution of Holliday junctions restores the
DNA templates. An alternative pathway for DSB repair is nonhomologous end-joining
(NHEJ). In this case, the two broken ends are processed and ligated directly. NHEJ
generally leads to small DNA sequence deletions.
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1.4.5 Fanconi anemia pathway
FA is a human disorder caused by the mutation of different genes. The function of
these genes (at least 14) has not been entirely understood. However, strong indications
show that these genes, including the BRCA2 (known as FANCD1), engage in a standard
repair pathway of ICLs. The HR repair pathway is promoted via the FA pathway when the
FA cells are treated with crosslinks inducing agents. [69]. There is an intersect between the
FA pathway elements and other DNA damage repair pathways, including HR and NER.
The FA proteins and the steps involved in the pathway have been reviewed in detail
elsewhere [69, 70]
FA pathway plays a crucial role in eliminating ICLs, and recent studies using FA
cells as a model to understand the chemoresistance. The process starts when ICLs are
identified at approaching a replication fork. Followed by the monoubiquitination of
FANCD2/FANCI heterodimers, which allow the activation of damage response of DNA.
Despite ensuring sufficient repair process, the FA pathway also helps in the coordination
of the transcription process, which is achieved through HR and using corrective
mechanisms that prevent the occurrence of errors during chromosome segregation.
Mutations within FA genes increases cancer cells' sensitivity to cisplatin chemotherapy
[70, 71].
1.4.6 Base excision repair
BER is a DNA repair pathway that helps to fix damaged base. Different enzymes,
like glycosylases, are involved in this pathway. This cellular mechanism starts with
identifying the damaged base first. The AP site will then be formed after the hydrolysis of
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the N-glycosidic bond [72]. Figure 1.1.5 shows the BER pathway's main steps in the
presence of a damaged base in DNA.
The involvement of the BER pathway in repairing the ICLs was indicated [73].
More evidence suggests the involvement BER pathway following inducing DNA adducts
with different crosslink agents such as psoralen, mitomycin C, and cisplatin [74-76].
Clinical relevance has confirmed the involvement of deregulated proteins associated with
the BER pathway from different cancer types [74, 75, 76].
Several studies indicated that the sensitivity of cisplatin is significantly influenced
by BER [76, 77, 78]. Some factors, such as Apurinic or apyrimidinic endonuclease (APE1),
contribute to resistance during cisplatin chemotherapy. For instance, a study showed that
overexpression of APE1 was linked to the chemoresistance. While the inhibition of APE1
in a lung cancer cell line, A549, leads to increased cisplatin sensitivity [76]. On the other
hand, there was no substantial proof that shows the association of platinum drug and the
repair mechanism found in some studies [79, 80, 81].
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Figure 1.1.5 Overview of the BER repair pathway. Glycosylase action creates an
apyrimidinic/apurinic (AP) or abasic site, which is processed by an AP endonuclease. a
single or multiple nucleotide are added, followed by ligation.
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By gaining more knowledge and insight regarding DNA repair pathways'
involvement in platinum chemotherapy, it becomes clear that different factors are involved
in the repair system that reduces the chemotherapy's effectivity, as previously mentioned
in section 1.5. Therefore, further investigations must also focus on different biological key
factors (e.g., epigenetic) may improve our understanding of the cytotoxicity of cisplatin.
Therefore, the role of epigenetic changes in cisplatin resistance should be investigated
(section 1.6).

For instance, essential insights from different studies indicated that

repositioning of genes in the interphase nucleus may play a role in cancer and
chemotherapy (more information in chapter 4).
1.5 Role of epigenetic changes in cisplatin resistance
In this section, the key factors of epigenetic contributions to cancer and
chemotherapy were reviewed, in particular, the role of chromatin remodeling, histone
acetylation and methylation.
1.5.1 Chromatin remodelling
The arrangements of nucleosomes in three-dimensional structure results in the
formation of chromatin. Recent studies have emphasized that chromatin structure plays a
vital role in gene expression. A nucleosome consists of histone octamer with a 146 base
pair length of DNA chain wrapped around it. Two copies each of H2A, H2B, H3 and H4
histone proteins comprises the central core of histone. [82]. At the centre of the core, two
copies each of H3 and H4 histone form a tetramer. A stable complex is formed by the
H3/H4 tetramer, and H2A/H2B dimers [83]. H1 is a linker Histone that is located between
each octamer.
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Depending on its function, there are two categories of chromatin: euchromatin and
heterochromatin. The majority of the genes are transcribed when euchromatin is
decondensed, which occur during the interphase; however, throughout the cell cycle,
heterochromatin remains condensed and contains mostly inactive genes (Figure 1.1.6) [84].
Chromatin structure plays roles in regulates all processes that occur in DNA, including
replication, transcription, recombination, and repair [85]. There are two ways to modify
and regulate the structure of chromatin; which known as post-translational modifications
(PTMs) and ATP-dependent chromatin remodelling activities. These two types of
chromatin modifications may result in modifications of the nucleosome in a particular area
in the chromatin structure; or generally [86, 87, 88, 89].
In PTMs, the N-terminal tail histone is modified by enzymes through different
modifications like methylation and acetylation. Many DNA metabolism processes are
regulated by the histone PTMs, including DNA repair and transcription; not only this, but
also PTMs was linked to DNA damage response [90, 91, 92]. For instance, histone H3,
at lysine 9 and lysine 14, acetylation is correlated with the NER [85]. This modification is
also found in the euchromatin on H3K4 trimethylation [93, 94, 95]. Moreover, histone
methylation is a key factor implicated in chromatin stability and cell cycle progression;
not only this but also an essential part in cell signalling following DNA damage occurred.
In the enzymes-based ATP-dependent chromatin remodelling, energy from ATP
hydrolysis is used for the modification of DNA-histone complex, which results in an
alteration in nucleosome structure [96]. This facilitates greater access of nucleosome DNA
to interacting proteins [97, 85]. There are four families of complexes which are involved
in the chromatin modellers, including ISWI, the switching defective/sucrose non-
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fermentable (SWI/SNF) INO80/SWR1 and CHD complexes. Chromatin structure is
modified by these complexes by moving/sliding, unwrapping, ejecting or restructuring
nucleosomes [98]. A subunit of the Snf2 family is contained by all of the ATP remodeller
complexes. This family comprises certain DNA repair proteins, such as RAD54 [99, 100].
Furthermore, the ATP-dependent chromatin remodelling factors are involved in
DNA repair. For instance, the SWI/SNF complex is needed for the excision of CPDs. Also,
the INO80 remodeller enhances XPC and XPA enrolments in the NER repair system [101].
There is considerable evidence indicates the involvement of the ATP-dependent chromatin
remodelling in DNA repair following induces the damage by genotoxic agents [85, 102,
103]. Therefore, it will be beneficial to understand the role of chromatin remodelling
involvement in repair of DNA damage induced by cisplatin.
For instance, the SWI/SNF complex modifies the appearance of chromatin in the
event that DNA damage has occurred. For the repair process to be effective, the chromatin
is unwound. The ICLs and the intrastrand adducts of cisplatin incomplete repairs were seen
in cells that lacked Brm and Brg1 (catalytic subunits of SWI/SNF) [104].
According to a study that examined the impact of cisplatin management on changes
that occur after the modification of histones in cancerous cells, it was found the histone H3
phosphorylation occurred at Ser-10, mediated by MAPK p38 pathway, which happened
after treatment with cisplatin. Additionally, histone H4 hyperacetylation occurred after the
utilization of the drug. Altogether, these results demonstrate the association between
modifications in the structure of chromatin could be changed following the cisplatin
chemotherapy [105]. Notably, histone deacetylase inhibitors (HDAC) are important in the
management of cancer as they effectively control regulatory genes in the cell-cycle. In
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guinea pigs, sodium butyrate which is an HDAC offered protection against ototoxicity of
cisplatin by single-dose administration. This makes HDAC plausible for possible clinical
use when patients undergo chemotherapy using cisplatin considering that the HDACs have
minimal side effects [106]. Therefore, it is essential to investigate other epigenetic key
factors such as histone acetylation and methylation to understand cancer and chemotherapy
better.
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Figure 1.1.6 Schematic of histone methylation and acetylation in the chromatin.
Adding methyl groups to the tails of histone core cause histone methylation, which produce
condensed state of chromatin known as heterochromatin, which lead eventually to
transcriptional repression. Adding acetyl groups to lysine residues in the N-terminal tails
of histones lead to histone acetylation, which produce a relaxed state of chromatin known
as euchromatin, which lead eventually to active transcription status.
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1.5.2 Histone acetylation
Chromatin structure is very dynamic, and changes occur in response to
environmental and extracellular signals [107]. One important chromatin modification is the
histone tail acetylation, which alters accessibility of DNA to regulating enzymes by
transforming the structure of chromatin from compact to relaxed which is permissive of
gene expression [108, 109]. The acetylation status is ultimately determined by the balance
between histone acetyltransferase (HAT) and histone deacetylase (HDAC) activities
(Figure 1.1.7) [110]. Histone acetylation is involved in mitosis and meiosis, cellular
differentiation, DNA damage, DNA transcriptional regulation, DNA replication, and
circadian rhythms [111, 112, 113, 114].
Based on structural homology, enzymatic activity, and cellular localization,
mammalian HDACs are divided into four classes [115, 116, 117, 118]. Class I HDACs
interact with histones and other proteins (HDAC 1, 2, 3, and 8) and are mainly nuclear
[119, 120], whereas class II HDACs (HDAC 4, 5, 6, 7, 9, and 10) are tissue-specific and
can be both cytoplasmic and nuclear [121]; Both class I and class II enzymes are inhibited
by most of the HDAC inhibitors [119, 121]. Sirtuins (SIRTs1 – 7; silent information
regulators) is considered as a class III HDACs. They are not responsive to majority of
HDAC inhibitors but require the cofactor NAD+. Lastly, HDAC11, which is a class IV
HDAC, is expressed in the nucleus. It is homologous to class I and class II HDACs (Table
1.1.2) [121, 122].
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Table 1.1.2 Classification of HDAC family

Class

Members

Subcellular
localization

HDAC1

Nucleus

HDAC2

Nucleus

HDAC3

Nucleus

HDAC8

Nucleus/cytoplasm

HDAC4

Nucleus/cytoplasm

HDAC5

Nucleus/cytoplasm

HDAC7

Nucleus / cytoplasm
/ mitochondria

HDAC9

Nucleus/cytoplasm

HDAC6

Mostly cytoplasm

HDAC10

Mostly cytoplasm

III

sirtuins in mammals
(SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7)

-------------

IV

HDAC11

Nucleus

I

II
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In the transcriptional activation HATs are involved, and in humans, five families of HATs
are present. GNAT, p300/CBP, MYST, TF-related HATs, and NR co-activators are the
nuclear HAT families. The first recognized family of HATs are Gcn5 (GNAT) related Nacetyltransferases. In eukaryotes, Gcn5 homologs are highly conserved proteins and are
noted in numerous organisms [123].
Mutation, overexpression, or translocation can alter the HAT and HDAC activity,
therefore disrupting the balance between acetylation and deacetylation. Consequently, they
contribute to cancer hallmarks; these epigenetic alterations have been observed in different
types of malignancies including different types of cancer (breast, prostate, colorectal, and
ovarian cancers) [119, 124]. Alterations in acetylation participate in carcinogenesis by
silencing the promoters of tumor suppressor gene (such as p21) [123, 125], abnormal
recruitment of HATs or HDACs or activation of repressed genes [119].
Once DNA binds to cisplatin agents, adducts of platinum-DNA components are
produced. The intact structure of chromatin dramatically reduces the access of DNA by
cisplatin, while using HDAC inhibitors makes DNA easily accessible to the agents due to
the fact that they relax the chromatin structure [126].
The modification of histone enables the optimal function of chromatin as well as
determining its structure. Currently, it has been discovered that histone acetylation is
important in DNA repair and the transcription process, and several reports indicate a link
between cisplatin resistance and HAT gene expression [127].
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Figure 1.1.7 Schematic of Histone acetylation and deactylation. Histone
acetyltransferase (HATs) adds acetyl groups (Ac) onto histone tails, which cause
nucleosome opening thus help transcription factors to be in contact with DNA and initiate
gene transcription. Histone deacetylases (HDACs) eliminate the Ac from the histone tails,
which cause a closed chromatin structure
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1.5.3 Histone methylation
Methyl groups are transferred from S-adenosylmethionine to lysine or arginine
residues of histone H3 and H4 by histone methyltransferases (HMT) [128]. Lysine 20 of
amino terminal end of H4 and lysine 4, 9 and 27 of amino terminal ends of H3 are
methylated frequently [129]. HMTs are classified into three different groups based on the
structure and sequence of their catalytic domains: 1) SET domain containing
methyltransferases 2) Arginine methyltransferases and 3) Dot 1 like lysine
methyltransferases [130]. Four subfamilies of SET domains have been identified namely,
the SET1 family, the SUV39 family, the SET 2 family and RIZ family [131]. Arginine 3
on histone H4 is methylated by protein arginine methyltransferase (PRMT1) which is a
histone methyltransferase [132]. This methylation by PRMT1 seems to be vital in vivo for
the maintenance or establishment of a broad range of "active" chromatin modifications.
Co-activator-associated arginine methyltransferase 1 (CARM1) is involved in enhanced
deposition of arginine 17 methylation [133].
Epigenetic factors such as DNA methylation and histone modification help in
suppressing tumor suppressor genes. The modification which takes place at H4 and H3 is
achieved through lysine methylation and H3-K9 methylation promotes the suppression of
cancerous cells [134] The pharmacodynamic effects of drugs in DNA methylation are
significant in the histone methylation process. In this case, the onset of drug resistance in
regard to cisplatin in the case of neuroblastoma cells showed that DNA methylation is
dramatically relevant in the process [135].
In regard to ovarian cancer and epigenetics, many experts have studied and
reviewed many factors such as PAR-4, modified regulation TMS1/ASC, DAPK, LOT1,
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BRCA1 hypermethylation, [136,137,138,139,140]. Moreover, in ovarian cancer, some
enzymes such as H3K9 methyltransferase G9a are found in large amounts in correlation
with negative health outcomes and reduced rate of survival [141]. Considering the benefits
of DNA methylation in the case of ovarian cancer, many drugs that specifically target the
methylation process have been manufactured. Some examples of manufactured drugs
include decitabine and 5-azacytidine which are both inhibitors of DNA methylation.
Unfortunately, the immunosuppressive impacts associated with the use of these drugs have
made their use limited [142]. Nonetheless, ovarian cells that are platinum-resistant
2008/C13 were shown to become sensitive to carboplatin whencombined together with
azacytidine through preheating [143].
Collectively, these facts provide additional evidence regarding the role of
epigenetic changes in cancer and chemotherapy. Moreover, the DNA repair systems have
a substantial effect on decreasing the chemotherapy's effectivity, as reviewed in section
1.4. However, despite all these findings, the chemoresistance of cisplatin is not well
understood. Therefore, further investigation should be conducted in other relevant
biological aspects. It is essential to identify approaches that indicate the mechanism of
cisplatin-induced DNA damage and demonstrate the DNA repair systems' involvement,
which will help us to understand the mechanism(s) of chemoresistance better.
Identification of ways to measure the damage will help to improve our knowledge about
the chemoresistance, thereby refining current disease treatment. Therefore, section 1.6 will
briefly described standard approaches to measure the DNA damage induced by cisplatin
and the repair systems' involvement.
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1.6 Methods to detect DNA damage and repair induced by cisplatin
Several factors dramatically target DNA, including chemotherapeutic drugs,
oxidative stress, certain environmental carcinogens, DNA alkylators, and UV radiation
exposure, which interfere with DNA structure. Exposure to these agents results in strand
breaks and may lead to mutation [144,145]. Cisplatin is a chemotherapeutic drug that
induces DNA damage via crosslink formation [146,147]. However, following cisplatin
induced DNA adducts, DNA repair mechanisms are activated to repair the damaged DNA
(section 1.4), making the treatment less effective [148]. To find a way to understand the
mechanism(s) of chemoresistance better, section 1.6 explores the standard approaches that
are commonly used to measure the DNA damage and the repair systems' involvement.
1.6.1 Polymerase chain reaction (PCR)
The PCR is beneficial in detecting DNA damage as the amplification process often
comes to a halt after encountering a damaged site. During the use of this technique, specific
regions of DNA are replicated, observed with the help of agarose gels that analyze DNA
fragments depending on the percentage of the gel [149].
1.6.2 The comet assay
In this method, the breaks that occur in DNA, induced by cisplatin, could be
measured using single-cell gel electrophoresis. This technique involves putting cells in an
agarose gel placed on a microscope slide, which is then lysed with salt and detergent to
produce nucleoids composed of supercoiled loops connected to the nuclear matrix. At high
pH, the electrophoresis forms a structure whose appearance is more like comets when
observed using fluorescence microscopy. The total DNA breaks are represented by the
intensity of the relative relationship between the head and the tail of the comet [150]. Also,
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in this assay, it is possible to monitor the repair process of DNA through treating cells with
cisplatin that induces DNA damage and then incubating them at 37 °C to allow the cells to
repair the damage [150].
1.6.3 Comet-FISH
This technique works by detecting repair and DNA damage in certain regions on
the genome [151]. The method has been successful in several studies where specific probes
for gene and chromosomes are utilized in regard to DNA damage in the comets (reviewed
in [152]).
In a single cell, specific gene localization domains can be determined by combining
Fluorescence In-Situ Hybridization (FISH) and comet assay. Fluorescent signals identify
the extent of damage and repair in DNA at particular sites and their total number.
1.6.4 Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL)
assay
TUNEL is a beneficial method to detect DNA fragments whereby the free terminals
of DNA are fluorescent so that apoptosis can be observed using a fluorescence microscope
[153]. The TUNEL assay can also be used to detect breaks that occur in double stranded
DNA [154, 155].
1.6.5 Enzyme-linked immunosorbent assay (ELISA)
Different substances, such as hormones, antibodies, proteins, and peptides, can be
quantified and detected in this assay. When it comes to the quantification of DNA damage,
competitive ELISA is a frequently used immunological approach for the process. Different
kinds of ELISA use enzymes such as peroxidase and phosphatase to detect major
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antibodies. ELISA can be classified into four major types: direct, indirect, competitive, and
sandwich.
There is an antigen on a surface during ELISA, which is then combined with the
enzyme-linked antibody. Detection can be achieved by evaluating the conjugated enzyme
activity together with a substrate where a product that can be measured is formed. The
interaction between the antigen and the antibody dramatically influences the assay's
success rate [156]. Therefore, ELISA is an excellent approach to detect and semi-quantify
cisplatin-induced DNA adducts in ovarian cancer cell lines, especially with an antibody
that recognizes cisplatin DNA adducts (including interstrand crosslinks, intrastrand
crosslinks, and monoadducts). In section 2.2.14, measuring the cisplatin-induced DNA
adducts was explained in detail by using ELISA.
1.6.6 Immunohistochemistry
This immunohistochemical assay is usually performed on tissue and also different
samples (cells) that are fixed. During fixation, samples are treated with RNase and
proteases to remove RNA and protein. Afterward, propidium iodide is used to counterstain
cells so that visualization of nuclei in cells that are adduct-negative can be achieved in
immunofluorescence. It is a powerful technique that can be useful even with small amounts
of samples and can also recognize adducts in individual cells in the tissue [157].
1.6.7 Immunological assay
The immunological assay is very specific and sensitive. In this assay, a small
amount of DNA is considered so that when detecting small adduct levels. The immunodot-blot assay was utilized to detect 6-4PPs and CPDs and the Dewar valence isomers of
the components under ultraviolet-irradiated mammalian cells [158].
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1.6.8 High-performance liquid chromatography-mass spectrometry (HPLC-MS)
The HPLC-MS is also specific and sensitive but has a significant shortcoming. The
assay is not useful when it comes to the detection of oxidative base damages, particularly
guanine. This is attributed to premature elution in liquid chromatography. Electrospray soft
ionizing characteristic enables the assessment of DNA adducts induced by chemicals [159,
160], CPDs, and 6-4PPs induced by UV exposure.
1.6.9 Gas chromatography–mass spectrometry (GC-MS)
The GC-MS uses the principles of mass spectrometry and gas chromatography to
detect several components in a sample [161]. This technique is widely used when it comes
to the evaluation of oxidative DNA damage, given its characteristic of identifying many
products of base modification [161].
As previously explained in section 1.6, several approaches are currently utilized to
detect different types of DNA damage and repair. However, there exist some benefits and
shortcomings in these approaches (reviewed in detail in [162]). Therefore, it is essential to
consider improving these approaches and using different detection techniques that reveal
the severity of the damage and quantify DNA damage and repair from different aspects.
Altogether, these strategies will help to understand the mechanism(s) of chemoresistance
better and improve cancer treatment.
Conclusively, ovarian cancer is one of the highest diagnosed reproductive cancers
in women. The main routes to treat ovarian cancer are invasive surgery and chemotherapy
(including cisplatin in combination with other chemotherapeutic drugs). The chemotherapy
has proven to be effective in some patients; however, a high percentage of patients relapse
after the initial treatment due to abnormally high activity of their repair systems or
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mutations occurring in genes sensitive to chemotherapy. Therefore, this thesis investigates
DNA damage and genomic organization in the cellular response to platinum chemotherapy
in ovarian cancer cells.
1.7 Hypothesis and specific aims
Several platinum compounds, including cisplatin, are currently used as anticancer
drugs to treat ovarian cancer. However, ovarian cancer patients often develop
chemoresistance to current platinum/taxane chemotherapy regimens either during initial
treatment or upon recurrence, which leaves patients with no alternative treatment options.
The mechanisms responsible for acquired tumor chemoresistance remain unclear. It is
hypothesized that differences in the formation and repair of platinum-derived DNA adducts
will exist between chemoresistant and chemosensitive ovarian tumor cells. Therefore, the
purpose of this thesis was to investigate the basis of chemoresistance in ovarian cancers.
Also, to gain knowledge in knowing the modifications that exist in sensitive cell lines
compared to the resistant cell lines. This can be achieved by understanding their response
to DNA damage and repair capacity (chapter 3). Furthermore, it is hypothesized that there
is a difference in the organization of chromatin in chemosensitive and chemoresistant
ovarian cancer cell lines, and gene repositioning and copy number changes are associated
with resistance to chemotherapy in ovarian cancer cell lines (chapter 4).
In order to achieve the goal of this thesis, the following aims have been identified:
Aim 1. To examine the difference in the DNA damage response in chemoresistant
and chemosensitive ovarian cell lines.
Aim 1A. To examine changes in the DNA damage response with acquired
chemoresistance cell line.
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Aim 2. To investigate the potential role of gene positioning and copy number
changes in chemosensitive vs chemoresistant ovarian tumor cell lines
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CHAPTER 2
MATERIALS AND METHODS
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2. Materials and Methods
2.1.1 Ovarian cell lines
This study utilized cells that were derived from ovarian cancers, the chemosensitive cell
lines were (A2780 and OCI-P5x), and the chemoresistant cell line was (SKOV-3). A2780,
human ovarian cancer cell line, is an established cell line that has been used in toxicity
testing and cancer genetic studies [163]. The A2780 ovarian cancer cell line,
chemosensitive, was taken from a patient with ovarian carcinoma (ECACC Ref No:
93112519). SKOV-3 is an ovarian cancer cell line that taken from the ascites of a Caucasian
female with an ovarian serous cystadenocarcinoma (ECACC Ref No: 91091004). SKOV3 cells are resistant to several cytotoxic drugs including diphtheria toxin, cisplatin and
adriamycin. The A2780 and SKVO-3 cells, were purchased from the European Collection
of Cell Cultures, ECACC (Louis, MO, USA). OCI-P5x is a primary ovarian cell line,
established from a human high-grade serous ovarian carcinoma [164]. OCI-P5x cells were
purchased from the Live Tumor Culture Core facility at the University of Miami (Miami,
FL, USA).
2.1.2 Materials for cell culture
RPMI 1640 culture medium, McCoy’s 5A culture medium, fetal bovine serum (FBS),
GlutaMax, 10X trypsin-EDTA, crystal violet, and phosphate-buffered saline (PBS) were
obtained from Fisher (Waltham, MA, USA). Cis-diamineplatinum (II) dichloride
(cisplatin) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Ovarian Carcinoma
Modified Ince medium (OCMI ) is a specific medium and was used to culture the ovarian
cancer cell line OCI-P5x. OCMI was obtained from the Live Tumor Culture Core at the
Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami.
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Dimethyl Sulfoxide (DMSO) was obtained from Corning (Corning, NY, USA). The cell
culture flasks, petri dishes, and six well plates were obtained from Fisher (Waltham, MA,
USA).
2.1.3 Materials for the alkaline comet assay
Potassium hydroxide, sodium chloride, sodium hydroxide, ethylenediaminetetraacetic
acid, disodium salt dihydrate, Tris base, hydrochloric acid, agarose, low melting point
agarose (LMA), and frosted microscope slides were purchased from Fisher (Waltham, MA,
USA). Human 8-oxoguanine DNA glycosylase 1 (hOGG1) and T4 endonuclease V
(T4endoV) were obtained from New England Biolabs (Beverly, MA, USA). Hydrogen
peroxide solution and pH-indicator strips were obtained from Millipore (Bedford, MD,
USA), while the propidium iodide solution was purchased from Sigma-Aldrich (St. Louis,
MO, USA). 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), Fisher
(Waltham, MA, USA).
2.1.4 Materials for FISH
FISH is a molecular cytogenetic method that utilizes fluorescent probes that bind only to
complementarity sequence of the genes of interest. The FISH experiments utilized the
following items: glass slides, 1 % pepsin solution, 1 % paraformaldehyde/PBS, and a
solution of 0.7 X saline sodium citrate (SSC)/0.3 % Tween 20 which were all purchased
from Fisher (Waltham, MA, USA). Dual color [fluorescein isothiocyanate (FITC), and
tetramethyl rhodamine isothiocyanate (TRITC)] labelled FISH probes, were used in this
study. BAC FISH probes labelled, with FITC or TRITC, were obtained from Empire
genomics (Buffalo, NY, USA). 4′,6-diamidino-2-phenylindole (DAPI) stain was purchased
from Vector Laboratories (Burlingame, CA, USA).
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2.1.5 Materials for ELISA
Acetic acid, ethanol, Tween 20, 1-Step™ Ultra TMB-ELISA substrate solution and the
stop solution for TMB substrates were purchased from Fisher (Waltham, MA, USA). The
QIAamp DNA mini kit was obtained from Qiagen (Valencia, CA, USA). DNA-bind clear
96-well polystyrene plates was obtained from Corning (Corning, NY, USA). Non-fat milk
was purchased from American Bio-Science Laboratories (Van Nuys, CA, USA). The
primary monoclonal antibody, which recognizes cisplatin DNA adducts (including
interstran, intrastrand crosslinks, and monoadducts), was purchased from Abcam
(Cambridge, MA, USA). The peroxidase-labelled anti-rat IgG, secondary antibody, was
obtained from Millipore Sigma (Temecula, CA, USA).
2.2 Methods
2.2.1 Cell culture
Cells were cultured using the supplier’s recommended media for all cell lines. Cells were
incubated at 37 °C in a 5% CO2 and humidified atmosphere. The A2780 ovarian cancer
cell line was cultured using RPMI 1640 medium supplemented with 10% (v/v) fetal calf.
The SKOV-3 ovarian cancer cell line was maintained in McCoy’s 5A medium
supplemented with 10% (v/v) FBS . The OCI-P5x ovarian cancer cell line was cultured in
OCMI medium. This medium was supplemented with epidermal growth factor (EGF),
cholera toxin and serum as described previously [164]. Cells were regularly tested for
Mycoplasma infection using a PCR-based assay developed in-house within the Florida
International University, cell culture core facility.
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Briefly, cells were cultured on the T75 flask and allowed to grow with the proper cell
culture media at 37 °C in a 5% CO2 and humidified atmosphere. Cells were split when
they were about 80% confluent. In detail, cells were washed with PBS, and 1X trypsinEDTA were added to flasks and were then placed in the incubator for 4 mins. Proper cell
culture medium was added, and cells were then centrifuged for 5 min. The pellets, in the
tube, were then resuspended in the proper medium (1 mL), and according to the proper
split ratio, cells were seeded to a new T75 flask with the cell culture medium then placed
to the incubator.
2.2.2 Cell freezing
Ovarian cells were washed with PBS and then trypsinized using 1X trypsin-EDTA. Prober
cell culture medium were then added, and cells were centrifuged for 5 min, and the pellets
were then resuspended in RPMI, McCoy’s 5A or OCMI medium containing 10 % DMSO.
Cells (1 × 106 cells/mL) were then aliquoted into cryopreservation tubes (1.8 mL, Thermo
Scientific), which were placed in liquid nitrogen later on.
2.2.3 Cell thawing
Cryopreservation tubes were thawed in a 37 °C water bath. The cells were transported to a
50 mL tube with 9 mL of specific culture medium. The tubes were then centrifuged at 1600
rpm for 5 min. After centrifugation, the supernatant was removed, and cells were mixed
with cell culture medium and subsequently transported to cell culture flasks and placed in
the incubator.
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2.2.4 Cell counting
After splitting cells, cells were resuspended in 1 mL of PBS and 50 µL of this cell
suspension was diluted immediately with 50 µL of trypan blue. A hemocytometer was used
to count the cells (Horsham, PA, USA); cells diluted with trypan blue were loaded onto
slides and cells were counted in all areas (four areas).
2.2.5 Cisplatin treatment
All cells were treated with cisplatin under sterile conditions with specific concentrations of
the chemotherapeutic agent, depending on the type of the experiment (0 - 300 µM).
Cisplatin powder, from Sigma-Aldrich (St. Louis, MO, USA), was dissolved in PBS to
prepare the stock solution (2 mM). The desired final concentrations were then prepared in
media and cell lines were treated with cisplatin for 1 h. Subsequently, the cell culture media
containing the cisplatin was removed and replaced with drug-free media for differing
periods of time (0 - 48 h) depending on the type of the experiment.
2.2.6 Ultraviolet Irradiation of Cells
UVB and UVC irradiation were achieved using Blak-Ray Lamps (model XX- 15M and
XX- 15S) (San Gabriel, California, USA). The UV intensity was determined with a UVX
radiometer to estimate the exposure time to accomplish the needed dose to induce the DNA
damage.
Briefly, ovarian cells were seeded in Petri dishes; the next day, cells were washed twice
with PBS and then irradiated in 1 mL PBS. The petri dish lid was removed prior to
irradiation. Subsequently, fresh media was added to the petri dish, and the cells were
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incubated in a 5 % CO2 incubator at 37 °C for different times (0 – 30 h) to assess DNA
repair in ovarian cancer cells.
2.2.7 Nuclear DNA Damage and Repair Measured by the Alkaline Comet Assay
The alkaline comet assay was used to measure the levels of DNA damage and repair in
chemoresistant and chemosensitive ovarian tumor cells. The comet assay is an accessible
assay popularly used to assess DNA damage. This assay typically recognizes DSB and
SSB; and it is based on electrophoresis of fixed cells in an alkaline buffer after lysing step.
The electric current helps the damaged DNA migrate far from the nucleus, creating the
comet shape; the comet tail's percentage is related to damage induced [165]. The comets
were visualized by fluorescence microscopy, which will be described in section 2.2.7.3.
The principle of the assay is illustrated in Figure 2.2.1. The comet assay is a beneficial
method to assess the ability of DNA repair [166]. That can be assessed by inducing damage
using a DNA-damaging agent and then incubate the cells in a 5 % CO2 incubator at 37 °C
for different times (0 – 30 h) to assess DNA repair in the cells by comparing all time points
to 0 h, which did not allow to repair.
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Figure 2.2.1 Schematic representation of the alkaline comet assay demonstrating how
comets are formed during the assay. Following the cell treatment with DNA-damaging
agent, cell, on glass microscope slides, will be lysed under high pH, which lead to remove
the cell membranes. Electrophoresis will pull the DNA out of the nucleoid body making a
tail, which has a comet shape. Slides will be then neutralized and washed with cold water
before drying overnight.
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2.2.7.1 Cell treatment for comet assay
Ovarian cancer cells were trypsinized and pelleted by centrifugation at 9000 rpm for 5 min.
The cells were then counted and 3 × 104 cells in 500 µL of PBS were placed in petri dishes
for UV irradiation (for the crosslinking experiments, cells were treated with cisplatin first
then were trypsinized as will be described in section 2.2.9.2).
2.2.7.2 The alkaline comet assay procedure
The alkaline comet assay was completed as described by Karbaschi et al. [167-169] (Figure
2.2.2.A). Following treatment, the cells were centrifuged at 9000 rpm for 5 min, and the
cell pellets were resuspended in 200 µL of 0.6 % LMA. The slides were previously precoated with 1 % normal melting point agarose (NMA). The mixture of LMA was made by
adding 120 mg LMA in 20 mL PBS. After that, 80 µL of the cells mixed with LMA was
placed onto pre-coated microscope slides with 1 % NMA and covered with coverslip. The
pre-coated slides with cells were then placed upon a slide chilling tray (Cleaver Scientific
Ltd., UK) (Figure 2.2.2B), to let the agarose to solidify. The coverslips were then removed
from all slides and transferred to a lysis buffer tank (100 mM EDTA, 2.5 M NaCl, 10 mM
Tris-base, 1 % of Triton 100, set pH 10) for the next day in the dark at 4 °C.
Following 12-16 h of lysis, the slides were placed in the washing box with cold water for
30 min. The electrophoresis step was then performed (25 V and 700 mA for 20 min) in the
dark. The slides were then neutralized with 0.4 M Tris-base (pH 7.0) for 20 min. Slides
were subsequently placed in washing box and incubated for the next day at 37 °C to dry.
For the staining step, slides were first rehydrated by placing them in water for 30 min; and
then stained with 2.5 µg/mL of propidium iodide solution and incubated for 20 min in the
dark. The slides were then washed, in the dark, with water for 20 min. The slides were kept
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in the dark until they were scored and analyzed. It was essential to carry out all the steps in
the dark to minimize additional DNA damage (Figure 2.2.2A). The comets were visualized
by fluorescence microscopy, and the tail intensity of the comets was measured using Comet
Assay IV Software (Perceptive Instruments, Haverhill, UK).
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Figure 2.2.2 (A) Principle of the alkaline comet assay procedure.
(i) Cells (3 × 104) were mixed with low melting point agarose. (ii) Then mixture was
layered onto microscope slides, pre-coated with agarose (1%), and the agarose allowed to
solidify (iii) The cells were lysed with high pH (pH 10) before (iv) washing with cold
water. The existence of strand breaks and high pH facilitate the DNA to unwind. (iv*) Only
in the enzyme-modified comet assay, repair enzymes (diluted with enzyme reaction buffer)
were added on slides in this step. (v) Electrophoresis carried the DNA out of the nucleoid
body creating a tail. The % Tail DNA (the quantity of DNA in the tail contrasted with the
head) is relative to the initial quantity of DNA damage. The slides were then (vi) allowed
to dry, (vii) neutralized and (viii) washed with cold water before (ix) drying overnight in
the incubator 37 °C. Next, further (x) slides being rinsed in cold water, the slides were then
(xi) PI stained, (xii) washed and finally (xiii) the comets were visualized by fluorescence
microscopy, and the tail intensity of the comets was measured using Comet Assay IV
Software (Perceptive Instruments, Haverhill, UK). This figure reproduced from (Karbaschi
and Cooke, 2014).
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Figure 2.2.2 (B) Demonstration of the slide chilling tray (Cleaver Scientific Ltd., UK).
The tray can carry up to 26 slides on both sides, while the ice pack can be placed underneath
of the tray to keep the slides cold and allow the LMA, on the slides, to solidified after
seeding the cells.
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2.2.7.3 Comet image scoring
Images of comets were at 40 x using an on-line charge-coupled device camera. The tail
intensity of the comets was measured using comet assay IV software (Perceptive
Instruments, Haverhill, UK). Fifty cells per gel (100 cells in duplicate slides) were scored,
and the percentage of tail DNA was measured for each comet in an individual replicate out
of three replicates (Figure 2.2.3). During the scoring, the comets located in the edges of the
gels were excluded from scoring to avoid any misrepresented comet to the damage.
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(A)

(B)

Figure 2.2.3 Example of comet images and DNA damage analysis using comet assay
IV software. (A) control has minimal levels of DNA strand breaks, so the DNA remains
complexed with the nucleoid body, whereas in (B) DNA strand breaks allow the migration
of the DNA (under electrophoresis) away from the nucleoid body something along these
lines. Electrophoresis carried the DNA out of the nucleoid body creating a tail. The relative
size of the tail is an indicator of DNA damage. Percentage tail DNA and tail moment are
the two most often parameters to analyze comet assay results. The comet assay IV software
(Perceptive Instruments, Haverhill, UK) helps to characterize and quantify the degree of
DNA. The software draws a box around the comet, which indicate the beginning of the
comet head (blue line), the middle of the head (green line), and the end of the comet tail
(purple line). These lines provide the software with the amount of DNA damage in each
comet.
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2.2.7.4 Analysis of base excision repair
BER was measured in all ovarian cancer cell lines, using the hOGG1-modified comet assay
as described previously [170, 171]. The hOGG1 repair enzyme was used to recognize and
remove oxidized purines (such as 8-oxodG) in the DNA of the ovarian cell lines. Inducing
oxidized purines, e.g. by H2O2 exposure, and then studying their removal, using the
hOGG1-modified comet assay provides an indication of the BER ability for the cell lines
studied. hOGG1 acts both as a N-glycosylase and an AP-lyase. The N-glycosylase activity
removes damaged purines from double stranded DNA, producing an apurinic (AP) site.
The AP-lyase action cleaves 3´ to the AP site leaving a 5´ phosphate and a 3´-phospho-α,
β-unsaturated aldehyde, which, under the alkaline conditions of the comet assay, becomes
a detectable single strand break.
2.2.7.4.1 hOGG1-modifed comet assay
The comet assay was performed as described in 2.2.7.2 with the following changes; cells
were treated with 50 M H2O2 and allowed to repair in an incubator for different periods
of time (0, 1, 2, 6, 12, and 24 h). The time points were selected with the consideration of
ability of the cells to be fully repaired. DNA damage was then measured using hOGG1modified comet assay, with some modifications [167, 168]. After finishing the lysis step
(Figure 2.2.2), 1X enzyme reaction buffer (ERB) was made as 20 mL of 10X ERB (9.532
g of HEPES, 7.46 g of KCl, 186.2 mg of Na2EDTA, and 200 mg of BSA dissolved in 100
mL of ddH2O, pH 8.0) diluted in 180 mL of cold water. Afterward, the slides were placed
in the box for washing with 1X ERB for 10 min. All slides were placed in the incubator for
1 h, and 3.2 U/µL of hOGG1 enzyme, which was diluted in the enzyme reaction buffer (1X
ERB) (60 µL per gel), was added to all the gels and covered with a coverslip. The
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concentration of the enzyme was optimized as will be described in section 2.2.8.1. After
incubation, all coverslips were removed, and the alkaline comet assay was performed, as
described in section 2.2.7.2 (Figure 2.2.2 with using step iv*)
2.2.7.5 Analysis of nucleotide excision repair
Using a similar principle as described for BER, DNA damage that repaired by NER can be
induced into the cells of interest, and then the removal of that damage is studied as an
indicator of NER. Cyclobutane thymine dimers are DNA damage that can be detected using
the T4 endonuclease V (T4endoV)-modified comet assay. T4endoV cleaves the glycosyl
bond of the 5´ end of the pyrimidine dimer and the 3′-phosphodiester bond, resulting in
breakage of the DNA strand, which is detectable by the alkaline comet assay (ACA).
2.2.7.5.1 T4endoV-modified comet assay
The T4endoV modified comet assay was performed following the same procedure
described previously in section 2.2.7.2 with some modifications as described previously
[170, 173, 174]. Cells were exposed to UVB (0.5 J/cm2) and allowed to repair in an
incubator for different periods of time (0, 1, 2, 6, 12, and 24 h). The UVB dose response
was previously optimized and 0.5 J/cm2 is the optimum dose for all tested cell lines. The
time points (0 – 30 h) were selected with the consideration of ability of the cells to be fully
repaired; therefore, the period between the time points were short. Every gel was incubated
with 0.0001 U/µL of T4endoV enzyme diluted in enzyme reaction buffer (1X ERB) for 1
h at 37 °C in a humid atmosphere. The concentration of the enzyme was optimized and
mentioned in following section 2.2.8.2
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2.2.8 Optimization of comet assay analysis parameters
2.2.8.1 Optimization of hOGG1 concentration
Optimizing the concentration of hOGG1 enzyme was essential for studying the repair
ability in ovarian cancer cells. If the concentration of hOGG1 is too high, non-specific
nicking may occur, if it is too low, not all the oxidized purines will be discovered. Cells
were treated with 50 M of H2O2 and slides were then placed in lysis buffer. Cells were
treated with increasing concentration of hOGG1 (0.16, 0.32, 1.6, 4.0, 8.0 U/mL), and then
DNA damage was assessed using hOGG1-modified alkaline comet assay (as described in
section 2.2.7.4.1). A linear increase in the DNA damage with increase of hOGG1
concentration was observed in all ovarian cell lines. Between concentrations 4.0 U/mL and
8.0 U/mL, the activity level of the enzyme come to a plateau. For this reason, 4.0 U/mL of
hOGG1 was selected as the optimum concentration of this enzyme for detection of 8oxodG induced on the DNA of ovarian cell line
2.2.8.2 Optimization of T4endoV concentration
Optimizing the concentration of T4endoV enzyme was also important for studying the
NER ability in all ovarian cancer cell lines. If the concentration of T4endoV is too high,
non-specific nicking may occur, if it is too low, not all the thymine dimers will be revealed.
Cells were exposed to UVB (0.5 J/cm2) and slides were then placed in lysis buffer. Cells
were then treated with increasing concentrations of T4endoV (0.16, 0.32, 1.6, 4.0, 8.0
U/mL). The assay was then continued according to the T4endoV-modified comet assay,
based on the ACA method described in section 2.2.7.5.1. The concentration of the stock
provided by the company was high which lead to rapture the whole DNA and show no
comets after using serial dilution of the enzyme. The CPD were demonstrate at low
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concentration with all cell line at 0.0001 U/μL, where the increase of the tail in the comet
clear comparing to the other concentrations. The optimum concentration of T4endoV for
removal of CPD from ovarian cells was selected as 0.0001 U/μL.
2.2.8.3 Optimization of PI concentration
The concentration of PI plays important role for comet scoring; the optimum concentration
of PI will help the software to detect the comet easily. Therefore, it was important to
optimize the concentration of PI using the same supplier described previously in section
2.2.7.2 with some modifications. Cells were exposed to UVB (0.5 and 1.0 J/cm2) and slides
were carried out using the same procedure of comet assay in section 2.2.7.2. During the
staining step, slides were washed with cold water and stained with different concentrations
of PI (2.5, 3.0, 3.5, and 4.0 µg/mL) for 20 min. The comets were visualized by fluorescence
microscopy, to measure the tail intensity of the comets using comet assay IV software
(Perceptive Instruments, Haverhill, UK). The optimum concentration of PI was 2.5 µg/mL.
There was no significant different among all the concentrations following the exposure
with different doses of UVB; however, using higher concentrations showed some issues of
detecting the comets.
2.2.8.4 Optimization of microscope magnification for scoring comet images
Comet Assay IV Software was used to detect the DNA damage. The software is well
established and can detect the comet easily; however, it was important to optimize the
magnification used to have an accurate detection of the DNA damage for every single
comet. Two magnifications (20x and 40x) were investigated to determine the best detection
of the comets. The optimum magnification that show better detection of the comets was
40x.
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2.2.9 Detection and quantification of cisplatin induced DNA Interstrand CrossLinks (ICL)
2.2.9.1 ICL-modified alkaline comet assay
Cisplatin-induced DNA crosslink formation was examined using a modification of the
ACA. The principle of the assay is that the presence of ICL in DNA will retard the
migration of damaged DNA, formed following an oxidizing insult, in the comet assay. In
this instance, the shorter the comet tail, the greater the number of ICL (Figure 2.2.4 and
2.2.5) [172-174].
2.2.9.2 Cell treatment for ICL-modified alkaline comet assay
In time course experiments, the cells were treated with cisplatin (100 µM) for 1 h at 37 °C,
5% CO2, then cells were placed at 37 °C for different time points (0, 3, 6, 12, 24, 30, 48 h)
to measure the peak of the crosslink and repair ability. Cells were then treated with 0
(control) or 50 µM H2O2 (to induce a requisite number of strand break to create a DNA
tail). After treatment, the cells were pelleted (9000 rpm for 5 min), washed three times with
1 ml PBS and processed for the ICL-modified ACA. In the dose response experiments,
following the treatment with a DNA crosslinking agent for 1 h, cells were then placed in
agent-free media for 3 h. Cisplatin and formaldehyde were used as a crosslinking agent at
different concentrations (50, 150, 300 µM). Cells were then exposed to 0 (control) or 0.5
J/cm2 of UVB (to induce a requisite number of strand break to create a DNA tail). After
the exposure, the cells were pelleted (9000 rpm for 5 min) and processed for the ICLmodified alkaline comet assay. To study the effectiveness of the crosslinking agent in
different cell-DNA substrates, cells were treated with cisplatin (50, 100, and 200 µM) for
1 h at 37 °C, 5% CO2, then cells were placed at 37 °C for 3 h. Cells were then exposed to
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0 (control) or 0.05 J/cm2 of UVC (to induce a requisite number of strand break to create a
DNA tail). After the exposure, the cells were pelleted (9000 rpm for 5 min) and processed
for the ICL-modified alkaline comet assay.
Comet images were captured using florescence microscopy and analyzed by the Comet
Assay IV software. The tail moment for comets were evaluated, and the level of DNA
interstrand cross-linking was expressed as percentage decrease in tail moment compared
to H2O2 treated controls (2.2.7.9 and 2.2.7.10) and calculated according to the following
formula:
% decrease in tail moment = [1− ((TMdi − TMcu)/(TMci − TMcu))] x100
Where TMdi = tail moment of cisplatin-treated and H2O2 treated sample; TMcu = tail
moment of untreated with cisplatin, untreated with H2O2 (control); TMci = tail moment of
untreated with cisplatin, treated with H2O2 .
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Figure 2.2.4 A schematic representation of the principle of cross-link formation
induced by cisplatin. The comet assay is a sensitive technique that can detect DNA
damage induced by UV or H2O2. The longer the tail the comet has, the more DNA damage
present in the cell. (A) In the absence of cisplatin treatment, the DNA breaks migrate with
the current forming the comet shape. However, in the presence of the cisplatin, (B), and
with using the same dose of DNA damage agent, the tail become shorter as a result of the
formation of crosslinks.
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(B)
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Figure 2.2.5 Representative comet images illustrating ICL detection following
cisplatin treatment. Comet images with and without cisplatin treatment after inducing
strands breaks with hydrogen peroxide in an ovarian cell line (SKOV-3). The comets
showed a decrease in tail moment in response to cisplatin treatment (200 µM) in SKOV-3
cell line. Cisplatin was able to form crosslinks, resulting in a decrease in tail moment after
DNA damage induced by H2O2 (50 µM). (A) Control cells without any treatment, (B) Cells
were treated with H2O2 (50 µM) only, (C) Cells were treated with H2O2 (50 µM) and
cisplatin (200 µM).

61

2.2.10 Cell survival
The cell survival of the ovarian cancer cell lines used in this thesis was measured by the
clonogenic assay. The clonogenic assay is based on the capability of a single cell to grow,
or not, into a colony after being treated with a toxic agent (e.g., cisplatin).
2.2.10.1 Clonogenic assay
Ovarian cancer cells were harvested from cell culture flasks by trypsinization (section
2.2.1), counted (section 2.2.4) and seeded (100 cells/well) in six-well plates. Cells were
treated with different doses of cisplatin (10-100 M) at 37 °C for 1 h and then incubated
in drug-free media for 7 days to measure the ability of cells to produce colonies. During
this time, the plates were incubated without replacing media for a period long enough to
form colonies of at least 50 cells. For all three cell lines, 7 days of incubation after treating
with cisplatin was required to form colonies of at least 50 cells (The incubation time was
optimized as described in the following section 2.2.10.2). After incubation, cell culture
media was removed, and cells were washed with PBS. Cells were then fixed using 3:1
ethanol:acetic acid and clones were stained with 0.05 % crystal violet and counted under a
microscope. Clones containing more than 50 cells were counted and considered as
colonies.
2.2.11 DNA extraction
DNA extraction is an essential procedure that required by different assays that conducted
in this study like ELISA and inductively coupled plasma mass spectrometry. Following
cell treatment with DNA-damaging agent, DNA of treated and untreated cell were
extracted using a QIAamp DNA Mini Kit which was obtained from Qiagen (Valencia,
CA, USA) as described in the manufacturer’s protocol. Briefly, cells were trypsinized and
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pelleted by centrifugation at 9000 rpm for 5 min. The cells (5 × 106) were then resuspended
in 200 µL of PBS in a 1.5 mL tube. A protease solution (20 µL) was added to the cells and
vortexed for 15 sec. cells were then incubated at 56 °C for 10 min and centrifuged for 15
sec. Ethanol (96-100%) (200 µL) was then added and the tubes vortexed for 15 s and
centrifuged for 15 sec. Samples were then transferred to QIAamp mini spin columns
(provided with the kit) and centrifuged for 1 min at 8000 rpm. AW1 buffer (500 µL) was
then added to all the columns and centrifuged for 1 min at 8000 rpm. After that, 500 µL of
AW2 buffer was added to samples and centrifuged for 3 min at 14000 rpm followed with
another centrifugation at the 15000 rpm for 1 min. AE buffer (200 µL) was then added to
samples and incubated for 5 min at room temperature, then the concentrations of the eluted
DNA were measured. The concentration and purity of the extracted DNA were measured
utilizing a Nanodrop (Thermo Scientific, Madison, WI, USA).
2.2.12 Cytotoxicity
2.2.12.1 Cell Counting Kit-8
Cytotoxicity, induced by DNA-damaging agents, was measured using the Cell Counting
Kit-8 (CCK-8) (Dojindo Molecular Technologies, Gaithersburg, MD, USA). CCK8 is a
sensitive colorimetric assay for measuring cell viability. CCK8 contains a highly watersoluble tetrazolium salt, WST-8, which reduced by dehydrogenase activities in cells to
generate a yellow-color formazan dye, that is soluble in the cell culture media. The amount
of the formazan dye, produced by the activities of dehydrogenases in cells, is relative to
the number of living cells. Cells were seeded in a 96 well plate (5000 cells/well) and
incubated overnight at 37 °C, 5% CO2. Cells were then treated with increasing
concentrations of cisplatin (0, 1.56, 3.13, 6.25, 12.5, 25, 50, 100, and 200 µM). After
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incubation for 24 h, CCK-8 mixture (10 µL) was added to every well and the plates were
placed for 4 h at 37 °C, 5% CO2. The plate was read at 450 nm in a Biotech plate reader
(Winooski, VT, USA).
2.2.12.2 Measuring cell toxicity of triazole-modified nucleosides and/or their
enhancement with cisplatin efficiency in ovarian cell line
Triazole-modified nucleosides (8-(1-H-1,2,3-triazol-4-yl)-2′-deoxyadenosine (8-TrzdA)
and 8-(1-H-1,2,3-triazol-4-yl)-2′-deoxyguanosine (8-TrzdG)) are chemical compounds
that have a fluorescent property. These compounds were obtained from Dr. Stanislaw F.
Wnuk (Florida International University, Miami, FL, USA). Using these chemical
compounds in the presence of cisplatin is reported to enhance the effectiveness of the
chemotherapy treatment [175, 176]. Cell toxicity of triazole-modified nucleosides was
measured and their enhancement with cisplatin efficacy in ovarian cell line was measured
using CCK-8. Briefly, cell viability was measured by the CCK-8 assay using the in a
chemosensitive cell line (A2780) after 24 h of incubation with 8-TrzdG of different
concentrations. Five thousand cells were treated with both cisplatin (100 µM) and triazolemodified nucleosides to establish if these compounds enhanced the efficacy of the cisplatin
treatment in ovarian cell line. Moreover, these compounds were examined to see if they
could be incorporated into DNA using the A2780 chemosensitive cell line. Briefly, cells
were treated with 8-TrzdG (204.8 µg/mL) for 24 h, DNA was then isolated, and samples
were fragmented using a sonicator for 30 cycles (30 sec ON/Off). DNA samples were then
loaded in a 1 % agarose gel to observe if there was any fluorescence in the bands using UV
transilluminator source, or if the size of the DNA bands were larger compared to the
control.
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2.2.13 Quantification of platinum in DNA using Inductively Coupled Plasma Mass
Spectrometry (ICP-MS)
2.2.13.1 Cell treatment for ICP-MS
The chemosensitive cell lines and the chemoresistant cell line were treated with cisplatin
(100 µM) for 1 h at 37 °C, 5% CO2, and incubated in drug free media for 12 h. DNA was
extracted as described in section 2.2.11. Samples were then sent to measure the platinum
concentration in the DNA using ICP-MS. On different occasions, cells were also treated
with cisplatin for 1 h and incubated in drug free media for different time points (0, 12, and
24 h).
2.2.13.2 General procedure of ICP-MS
ICP-MS is an elemental analysis method which quantifies metals such as platinum in
samples at milligram to nanogram levels per liter. Ovarian cancer cell lines were treated,
as described in section 2.2.13.1, and the DNA extracted, as described in section 2.2.11. The
platinum concentration in the DNA samples was measured using ICP-MS by Dr. Natalia
Quinete (Florida International University, Southeast Environmental Research Center,
Miami, FL, USA).
Briefly, DNA samples (200 µL of DNA/platinum) were transferred to pre-cleaned 15 mL
tubes. 1 mL of concentrated nitric acid was added to samples and then heated for 2 h at 90
°C in the heating block. After cooling at room temperature, 100 µL of the internal standard
mix was added (to a final concentration of 10 µg/L) and the volume was made up to 10 mL
with HNO3 3%. Bismuth was used as internal standard. A laboratory procedure blank, a
spiked blank and a duplicate of the spiked blank were prepared and followed the same
procedure as the DNA samples extracted from the cisplatin treated ovarian cancer cell
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lines. Samples were directly analyzed by ICP-MS, SQ-KED (Single Quadrupole with
Kinetic Energy Discrimination) mode. A calibration curve was made for platinum from
0.05 to 20 µ/L (R2=0.999). After every 10 samples, the calibration curve verification
(CCV) and a blank were run to check the consistency of the calibration curve and any
contamination. All values were within the acceptable criteria and recoveries were 96115%. The method detection limit for platinum was 0.016 µg/L.
2.2.14 Detection and quantification of cisplatin induced DNA adducts
2.2.14.1 Cell treatment for ELISA
Ovarian cancer cell lines were treated with cisplatin (100 µM) for 1 h at 37 °C, 5% CO2,
then the media was changed to drug-free media and incubated for different time points (0,
6, 12, and 24). DNA of all cells were extracted as described in section 2.2.11.
2.2.14.2 ELISA
ELISA was used to detect and semi-quantify cisplatin induced DNA adducts in ovarian
cancer cell lines following cisplatin treatment. The ELISA was optimized as described in
section 2.2.14.3, below. Following the cell treatment with 100 µM of cisplatin (section
2.2.5), DNA was extracted as described in section 2.2.11. Following DNA denaturation,
the 96 well plate was coated with 50 µL/well DNA solution (50 µg/mL), diluted in PBS,
and placed in the incubator for 1 h at 37 °C in a 5% CO2 and humidified atmosphere. After
the plate was washed 3X with PBS, open sites were blocked by 150 µL/well of a 4 % (w/v
in PBS) dried skimmed milk (Canton, MA, USA) and incubated for one hour at the
incubator; then the plate was washed 3X with PBS. The monoclonal anti-cisplatin DNA
adduct antibody (Abcam, Cambridge, MA) was diluted in the blocking solution (0.004
mg/mL) added to the plate (50 µL/well), and incubated for one hour at 37 °C. This antibody

66

binds to cisplatin-induced adducts in DNA. The plate was washed three times (300
µL/well) with PBS containing 0.05 % (v/v) Tween. The peroxidase-labelled anti-rat IgG
secondary antibody (Chemicon, Temecula, CA) was diluted in the blocking solution (0.16
µg/mL), and 50 µL/well was added to the plate and incubated for one hour at 37 °C. The
plate was washed three times (300 µL/well) with PBS containing 0.05 % (v/v) Tween. The
1-step slow TMB ELISA substrate solution was added (100 µL/well) in the dark for 15-30
min to allow the color to develop. Then the reaction was stopped using 0.16 M sulfuric
acid (50 µL/well). The plate was read at 450 nm in an ELISA plate reader (Winooski, VT,
USA). The human keratinocyte line (HaCaT) was exposed to UV and DNA was extracted
and used as a positive control using thymine dimers as a positive control in the assay.
2.2.14.3 Optimization of ELISA conditions
It was important to test a range of parameters for the ELISA procedure to have reliable
results, maximizing antibody binding to the DNA adducts, while eliminating non-specific
binding. This was performed by optimizing different assay parameters, and then running
the ELISA as follows: coating the plate with Poly-L-lysine (Sigma), denaturation of the
DNA, concentration of bound DNA, choice of blocking solution (BSA and dry milk), and
concentration of primary and secondary antibodies.
Every condition of the assay was tested individually. Briefly, cells were treated, and DNA
isolated as described in section 2.2.11. and loaded on to the 96 well plate with or without
a boiling step (DNA was boiled for 10 min then cooled rapidly on ice). This step was
included to determine if the denatured DNA will have better binding to the ELISA plate.
The concentration of the DNA was also optimized using a serial dilution to determine the
optimum concentration of DNA (25, 50, 100, and 200 µg/mL). Moreover, the choice of
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blocking solution was based on preventing the nonspecific binding. Rat monoclonal
primary antibody (anti-cisplatin DNA adducts) was used in this study; and goat-anti rat
conjugated with Horseradish Peroxidase (HRP) was used as a secondary antibody. The
primary antibody was optimized using a serial dilution to determine the optimum
concentration to use in this study (1:250 to 1:4000), stock concentration was 1 mg/mL. The
plate was read at 450 nm in an ELISA plate reader (Biotech Instruments Inc, USA). After
optimizing all conditions separately, Corning 96-well polystyrene plate was used for all
experiments.
2.2.15 Evaluation of gene positioning in chemosensitive and chemoresistant ovarian
cancer cells
FISH is a molecular cytogenetic method that utilizes fluorescent probes that have sequence
complementarity to specific regions of the genome. FISH facilitates the enumeration of
genomic regions of interest and visualization of regions of interest in both metaphase
chromosome spreads and interphase nuclei. These labeled DNA probes hybridize with the
cytological targets in the sample and can be imaged by fluorescence microscopy (Figure
2.2.6). FISH has a wide range of applications to assess chromosomal abnormalities (e.g.,
deletions, duplications, and structural rearrangements). However, FISH is also utilized to
assess localization of genomic regions (e.g., chromosomes or genes) within the interphase.
It has been established that the genome is highly organized within the interphase nucleus,
this organization is evolutionarily conserved and cell-type specific and is believed to be
another level of epigenetic regulation of the genome. For example, nuclear position may,
in part, determine gene expression, DNA damage and repair amongst others.
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It uses fluorescently labeled DNA probes complementary to the DNA sequence of specific
genes (Table 2.2.1). The main goal of this aspect of the study was to determine if genes
involved in ovarian cancer and tumorigenesis were randomly or non-randomly organized
in the nucleus of the ovarian cancer cell lines in in this study (A2780, OCI-P5x, and SKOV3) and to assess the copy number of these genes in the different cell lines. Furthermore, a
secondary aim was to establish whether the nuclear localization of the investigated genes
differed between chemosensitive (A2780 and OCI-P5x) and chemoresistant cell lines
(SKOV-3).
2.2.15.1 Cell treatment for Fluorescence In-Situ Hybridization
Ovarian cancer cell lines were treated with cisplatin (100 µM) in T25 flask for 1 h at 37
°C, 5% CO2, then media was replaced with drug-free media and incubated for 12 h to
ensure to have a high percentage of DNA crosslinks. Cells were trypsinized and transferred
to a 15 mL centrifuge tube, which were centrifuged at 9000 rpm for 5 minutes. The
supernatant was removed, and the cell pellet was resuspended drop wise with 5 mL of 3:1
methanol: acetic acid. The sample was then centrifuged as described previously and the
dropwise fixation followed by centrifugation steps were repeated a further 2-3 times. The
dropwise fixation and resuspension of cells is a critical step to avoid cell clumping, as
assessment of gene positioning requires individual cells. Following cell treatment and
fixation, cell density was checked under a light microscope (40x phase contrast) by adding
a 2 µL drop onto a microscope slide, if samples had sufficient cell density and limited cell
clumping samples were subsequently stored at - 20° C until required for experiments.
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2.2.15.2 FISH
In preparation for FISH, fixed samples were removed from - 20° C, and 2-10 µL of the cell
suspension was placed onto a slide, amount of cell suspension added was determined to
achieve optimal cell density. Slides then were washed with PBS and dehydrated in an
ethanol series (70%, 80%, and 100%) for five min each and air dried. Slides were then
washed in ddH2O followed by rinsing in PBS before incubation in 4%
paraformaldehyde/PBS at 4 °C for 10 min; slides were then rinsed with PBS followed by
ddH2O at room temperature and another ethanol series was carried out at room temperature
for 2 min each and the slides air dried. FISH probes complementary to specific genes used
in this study are provided in Table 2.2.1. FISH probes were BAC probes spanning the gene
of interest and were obtained from Empire genomics (Buffalo, NY, USA). Each probe was
labeled with either a red or green fluorophore which facilitated a dual FISH approach and
allowed the detection of two different genes simultaneously in cell nuclei. FISH probes
were prepared as per the manufacturer’s guidelines, the probes: hybridization mix ratio was
1:1:3 (red FISH probe: green FISH probe: hybridization mix). The FISH probe mix was
then vortexed and pulse microfuged and subsequently pre-denatured at 73 °C, for 10 min
in a water bath. Following denaturation of the FISH probes in hybridization mix 10 µL of
probe was added to the slide and a 12x12 mm coverslip were placed on the slide (note,
amount of probe was increased or decreased depending on the size of the coverslip
utilized). Coverslips were sealed to the slide using parafilm to minimize probe evaporation.
After adding the denatured FISH probes and coverslips to slides, the slides were placed in
a hybrite (vysis) at 75 °C, for 90 sec and followed by hybridization overnight (16 h) at 37
°C in a humidified chamber. The hybridization was performed using a Thermobrite®
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Statspin Thermobrite® Statspin (Illinois, IL, USA). Once the hybridization period was
completed, the slides were washed in 0.4X SSC-0.3% tween to remove the coverslips at
room temperature. Then, the slides were placed in a pre-warmed solution of 0.4 X SSC0.3% Tween-20 at 73 °C and washed for 90 seconds to remove excess probe. Slides were
then placed in 2X SSC-0.1% tween for a 1 min wash at room temperature followed by an
ethanol series (2 min each). Finally, slides were air-dried and counterstained with DAPI
and were ready for capturing.
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Table 2.2.1 Putative genes involved in ovarian cancer formation and selected to
study gene positioning in chemosensitive and chemoresistant ovarian cancer.

Function

Genes

Tumor suppressor

BRCA1, BRCA2, NF1, PTEN, RB1, TP53

Intracellular
signalling/Transcription
regulator/Regulator of cell
signalling/Regulator of cell
division

BRAF, KRAS, MECOM, PAX3, CNNE1,
AKT3, CTNNB1, PAX3, FOLR1, NACC1,
ALG8

Table 2.2.1 Putative genes involved in ovarian cancer formation and selected to study gene
positioning in chemosensitive and chemoresistant ovarian cancer. As the fact that ovarian
cancer-associated genes are various, this study focuses on numerous upregulated genes as
examples to determine their roles in understanding the molecular etiology of ovarian cancer
and their possible role as analytical indicators. FISH technique helps to examine if these
genes are random or nonrandomly organized and if that changes between chemosensitive
and chemoresistant cells, and if treating the ovarian cells with cisplatin will make some
alteration on the ploidy or the organization.
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2.2.15.3 Image capture
Slides were examined on an Olympus BX-61 epifluorescence microscope supplied with a
cooled CCD camera and appropriate filters. Three single band pass filters for FITC,
TRITC, and DAPI were used in this study (Chroma Technology, Bellows Falls, VT,
USA). Images were captured using SmartCapture 3 (Digital Scientific UK). A minimum
of 100 cells were analyzed per FISH probe, per cell line, per condition (cisplatin treated
and untreated).
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Figure 2.2.6 Representation figure illustrating the radial analysis of OCI-5Px stained
for KRAS (green) and BRCA1 (red) genes and counterstained DAPI (blue) using FISH
technique. The radial analysis software measures the DAPI intensity and divides the
nucleus into five shells of equal area. Shell 1 is innermost and shell 5 is outermost. These
shells help to identify the location of the gene of interest. In the normal situation, two FISH
signals would be expected reflecting the expected diploid content of the cell. In the ovarian
cancer cell lines, some genes varied from the expected diploid content. For example, the
KRAS gene has three copies, which indicates a copy number mutation or amplification of
the KRAS gene in this cell.
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2.2.16 Statistical analyses
Statistical analysis was performed using GraphPad Prism (GraphPad, CA, USA). The data,
generated using comet assay, were analyzed using non-parametric t-tests (Mann Whitney)
to compare the values between the groups. Three independent experiments were
performed, and the data were represented as mean ± SEM. For the FISH experiments, The
Chi-squared goodness of fit (χ2) was utilized to evaluate if the organization of each gene
differed from being random (p < 0.05) and to compare differences between conditions
(cisplatin treated and untreated) in chemosensitive and chemoresistant cells. For the other
experiments, the statistical analysis was mentioned in the experiment section. Significance
limits were set at *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. I would like to
thank Dr. Marcus Cooke, Dr. Helen Tempest, and Dr. Changwon Yoo for giving me
guidance and help with data analysis.
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CHAPTER 3
EXAMINATION OF THE DIFFERENCE IN THE DNA DAMAGE RESPONSE
IN CHEMORESISTANT AND CHEMOSENSITIVE OVARIAN CELL LINES
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3.1 Introduction
Ovarian cancer is the ranked fifth in terms of leading cause of cancer related mortality in
women. Amongst the primary predisposing factors to the high rates of deaths is the tumors,
which develop resistance to current treatment modalities. Researchers have not identified
the strategies and treatments for reducing its vulnerability or possible regulatory
mechanisms of the tumor. Currently, the tumor debulking surgeries followed by
chemotherapy are considered the optimal treatment for patients with advanced ovarian
cancer. Although there are various chemotherapeutic approaches for the treatment of
advanced ovarian cancer, the combined therapy of cisplatin and paclitaxel is the most
common. The mechanisms responsible for acquired tumor chemoresistance remain
unclear. Cisplatin is clinically proven to be used for the treatment of numerous human
cancers However, many women with this disease may undergo relapse or even succumb to
the disease as a result of resistance to chemotherapy. Cancer cells resistance to the
antitumor drugs remains a significant impediment to effective treatment. Several research
studies have been conducted to investigate the molecular mechanism of such chemical
resistance to the cisplatin, but the mechanism has not yet been fully elucidated. The goal
of this study was to investigate the basis of chemoresistance in ovarian cancers. The Comet
assay can help in the measurement of ICLs repair and formation as well as their base
excision repair in chemosensitive (OCI-P5x and A2780) and chemoresistant (SKOV-3).
The idea is useful in the analysis of the potential DNA damages during formation or repair
at the initial stages of single cells. This chapter provides a basis to further improve our
understanding of the differential DNA damage response associated with chemosensitive
and chemoresistant ovarian cell lines. Elucidating the mechanisms of chemoresistance may
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ultimately lead to novel therapeutic interventions that may resensitize or prevent the
development of chemoresistance.
3.2 Methods
3.2.1 Ovarian cancer cell lines
Two chemosensitive ovarian cancer cells (A2780 and OCI-P5X) and one chemoresistant
ovarian cancer cell (SKOV-3) were used in this study. All the ovarian cells were cultured
according to the supplier’s recommended media and condition for each cell line (section
2.2.1 to section 2.2.4). Ovarian cancer cells were cultured in T75 cell culture flask and
allowed to grow with the appropriate cell culture media at 37 °C in a 5% CO 2 and
humidified atmosphere. For all cell lines, two groups were prepared, one as a control group,
and the other is treated with cisplatin.
3.2.2 Cisplatin treatment
Treated groups were treated with cisplatin (100 µM) for 1 h at 37 °C in a 5% CO2 and
humidified atmosphere (section 2.2.5). Subsequently, the cell culture media containing the
cisplatin was removed and replaced with drug-free media for differing periods of time (0 48 h) depending on the type of the experiment and placed at 37 °C in a 5% CO2 and
humidified atmosphere.
3.2.3 Clonogenic assay
Cells were treated with different doses of cisplatin (10-100 M) at 37 °C for 1 h and then
incubated in drug-free media for seven days to measure the ability of cells to produce
colonies. During this time, the plates were incubated without replacing media for a period
long enough to form colonies of at least 50 cells (section 2.2.10 and 2.2.10.1).
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3.2.4 The alkaline comet assay procedure
The alkaline comet assay was carried out as described by Karbaschi et al. [170-171] for
more detail review section 2.2.7 to 2.2.9.2.
3.2.4.1 Time course of DNA crosslink formation and repair in ovarian cancer cells
The comet assay was carried out to measure the level of DNA damage, and repair, induced
by chemotherapeutic agent. Ovarian cancer cells (A2780, OCI-P5x, and SKOV3) were
treated with 100 µM for 1 h and incubated with drug free media for different time points.
Cells were then treated with 0 (control) or 50 µM H2O2 to induce a requisite number of
strand break to create a DNA tail. The crosslink formation was assessed by comet assay.
3.2.4.2 DNA Crosslink formation in intact cells and nucleoid bodies from
chemosensitive and resistant ovarian cell lines.
The comet assay was carried out to measure the level of DNA damage induced by different
doses of cisplatin in different cell-DNA substrates. Ovarian cancer cells (A2780, OCI-P5x,
and SKOV3) were treated with cisplatin (50, 100, and 200 µM) for 1 h at 37 °C, 5% CO2.
Cells were then expose to 0 (control) or 0.05 J/cm2 of UVC to induce a requisite number
of strand break to create a DNA tail
3.2.4.3 Optimization of hOGG1 concentration for ovarian cell lines
The optimum conditions for hOGG1 required to be determined for the ovarian cancer cell
lines. To optimize the concentration of hOGG1 for deduction of 8-oxodG in ovarian cells,
these cells were treated with 50 µM of H2O2. A series of dilutions of the hOGG1 enzyme
was set up from the stocks (1,600 U/mL) in enzyme reaction buffer. The hOGG1 modified
comet assay was performed using different concentrations of hOGG1 for 60 min
incubation. Optimization of PI were also preformed, it was reviewed in section 2.2.8.3.
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3.2.4.4 Analysis of base excision repair
The hOGG1-modified comet assay was carried out to measure the repair of 8-oxodG after
hydrogen peroxide treatment. The remaining percentage of tail DNA was detected at
different time points immediately after the treatment, 1, 2, 6, 12, or 24 h. Ovarian cells
were treated with 50 µM of H2O2 and allowed to repair for different time points assessed
by hOGG1 modified comet assay.
3.2.4.5 UVB dose response
To measure the extent and linearity of CPDs and ALS induction in ovarian cells, a dose–
response following UVB was determined. The comet assay was carried out to measure the
level of DNA damage induced by several doses of UVB. Ovarian cells were exposed to 0,
0.25, or 0.5 J/cm2 UVB and then measured by T4endoV modified comet assay. T4endoV
modified comet assay was used to measure the induction of CPDs following UVB
irradiation.
3.2.4.6 UVC dose response
The comet assay was carried out to measure the level of DNA damage induced by several
doses of UVC. Ovarian cells were exposed to 0.025, 0.05, or 0.1 J/cm2 UVC and then
measured by comet assay.
3.2.4.7 Optimization of T4endoV concentration for ovarian cell lines
The T4endoV-modified comet assay was carried out to measure the repair in ovarian cancer
cells after irradiated them with UVB. Ovarian cells were irradiated with 0.5 J/cm2 of UVB,
and then then measured by T4endoV modified comet assay. T4endoV modified comet
assay was carried out to measure the CPDs. The stock enzyme which purchased from NEB
(biolab tech) was concentrated and it was important to optimize the concentration that will
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be used in the experiment. To optimize the concentration of T4endoV for removal of CPDs
on ovarian cell lines, cells were exposed to 0.5 J/cm2 of UVB. Different dilutions of the
enzymes were made from the stocks [10,000 U/mL] in enzyme reaction buffer. Following
the cell lysis step, ovarian cells were incubated with different concentrations of T4endoV
for 1 h before electrophoresis in alkaline buffer. Control samples were not irradiated but
incubated with different concentrations of T4endoV.
3.2.4.8 Analysis of nucleotide excision repair
The T4endoV-modified comet assay was carried out to measure the repair in ovarian cancer
cells after irradiated them with UVB. Ovarian cells were irradiated with 0.5 J/cm2 of UVB,
and then the cells were allowed to repair at the incubator for different time points (0, 1, 2,
6, 12, 24, or 30 h). In addition, group of cells were not irritated and used as a control to
measure the background level of DNA damage. Repair of the CPD in ovarian cells were
determined by the T4endoV-modified comet assay
3.2.4.9 Crosslink formation on ovarian cell with environmental and chemical agents
The comet assay was carried out to measure the level of DNA damage induced by different
doses of cisplatin and formaldehyde. Ovarian cells were treated with 0, 50, 150, or 300 of
formaldehyde/cisplatin and cells were then expose to 0 (control) or 0.5 J/cm2 of UVB to
induce a requisite number of strand break to create a DNA tail. The crosslink formation
was then assessed by comet assay.
3.2.5 ELISA
Ovarian cancer cell lines were treated with cisplatin (100 µM) for 1 h at 37 °C, 5% CO2,
then the media was changed to drug-free media and incubated for different time points (0,
6, 12, and 24).
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DNA was loaded to the coated plate with/without boiling step (10 min then cooled rapidly
on ice). Anti-cisplatin DNA adducts were used as a primary Ab (1:1000, 1 mg/mL), and
goat- anti rat were used as a secondary Ab (1:5000, 0.8 mg/mL). As a positive control,
thymine dimer primary Ab were used (1:1000, 2 mg/mL) after exposing the cell to UVB
(1 J/cm2), and goat- anti mouse were used as secondary Ab (1:2000, 2 mg/mL).
3.2.6 Quantification of platinum in DNA using Inductively Coupled Plasma Mass
Spectrometry (ICP-MS)
ICP-MS is an elemental analysis method which quantifies metals such as platinum in
samples at milligram to nanogram levels per liter. Ovarian cancer cell lines were treated,
as described in section 2.2.13.1, and the DNA extracted, as described in section 2.2.11. The
platinum concentration in the DNA samples was measured using ICP-MS by Dr. Natalia
Quinete (Florida International University, Southeast Environmental Research Center,
Miami, FL, USA) as described in section 2.2.13.
3.2.7 Measuring cell toxicity of triazole-modified nucleosides and/or their
enhancement with cisplatin efficiency in ovarian cell line
Cell viability of A2780 cells was assessed by CCK-8 following the 24 h incubation with
8-TrzdG of different concentrations. Using this chemical compound was reported to
enhance the effectiveness of cisplatin as a chemotherapeutic agent. The aim of using this
approach was to demonstrate if the chemical compound was able to enter the cells and
integrate with the DNA using the cell culture model. The chemical compound, 8-TrzdA,
was reported previously to work effectively by other lab group who designed the
nucleosides. They demonstrated that 8-TrzdA 5'-triphosphate was incorporated into duplex
DNA [177]. Therefore, two group of cells were used, and treated with increased
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concentration of 8-TrzdG. After 24 h, and only one group the cells were treated with
cisplatin (100 µM) to demonstrate if that will increase the effectiveness of cisplatin with
the chemosensitive cell line in the presence of the chemical compound.
3.3 Results
3.3.1 Treatment with cisplatin cause a decrease in ovarian cancer cell survival
Clonogenic assay was carried out to measure the survival of the ovarian cancer cell lines.
Clonogenic assay is based on the capability of a single cell to grow, or not, into a colony
after being treated with a certain agent (e.g., cisplatin). In Figure 3.3.1, the chemosensitive
cells showed low survival rates after seven days, in response to increasing doses of
cisplatin, in both A2780 and OCI-P5x cell lines This indicated the sensitivity of these cell
lines compared to the chemoresistant cells, (SKOV-3) (P< 0.05). There was a rapid
reduction in survival rate observed in the chemosensitive cell line (A2780) with the
increasing concentrations of cisplatin.
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Figure 3.3.1 Chemoresistant cells have a significantly cellular cell survival in response
to cisplatin compared to chemosensitive cell lines. SKOV showed lower survival rates
compared to the chemoresistant cell (SKOV-3). Cells were exposed to cisplatin (0100 M) and stained 7 days after seeding for A2780, SKOV-3, and OCI-P5x. Data
represent the mean +/- SEM from three experiments. * P< 0.05
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3.3.2 Chemoresistant tumor cells are refractory to the formation of cisplatininduced DNA crosslinks
As shown in Figure 3.3.2, the data revealed considerable differences among the ovarian
cancer cell lines in response to cisplatin treatment. It was observed that the peak of
cisplatin-induced crosslink formation for all three cell lines was at 12 h, which was
confirmed by ICP-MS (Figure 3.3.3), we noted a significant attenuation (P < 0.0001) of
ICL formation in the chemoresistant cell line SKOV3, compared to the chemosensitive
lines. In the first 12 h, there were no significant different between both chemosensitive cell
lines however, after 12 h, there were slight reduction of DNA crosslinks in A2780 compare
to the OCIP5x cell line. At 48 h the A2780 cells reached the baseline levels while the
SKOV3 cell line still had around 20 % of DNA crosslinks remaining.
Moreover, the platinum concentration in DNA samples was quantified using ICP-MS in
all ovarian cells after cisplatin treatment. As Figure 3.3.3 shows, there was a positive
correlation observed between DNA crosslinks and platinum concentration in the
chemosensitive cell line, OCIP5X, at 12 h post cisplatin treatment. The chemosensitive cell
line had a significant increase in DNA crosslinks, and the final platinum concentration was
higher than the chemoresistant cell line, SKOV3. As Figure 3.3.3 shows, the incubation
with drug-free media for different time points following the treatment with cisplatin led to
a significant increase of platinum concentration in the chemosensitive cell compared to the
chemoresistant cell. As shown in Figure 3.3.3A, the chemosensitive cell, OCIP5X, had a
significant increase in platinum concentration than the chemoresistant cells, SKOV3, at all
time points (p < 0.0001). OCIP5X had the highest platinum amount at 0 h post-treatment
with 65 ug/g, while A2780 39 ug/g and SKOV3 had 35 ug/g. At 24 h post-treatment,
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OCIP5X had a significant increase of platinum concentration comparing to the
chemoresistant cell line, SKOV3.
Moreover, a slightly decreased platinum concentration was noted in A2780 (42 ug/g) 24 h
post the treatment. ELISA was also used to detect and semi-quantify cisplatin-induced
DNA adducts in the chemosensitive and chemoresistant cells following cisplatin treatment,
as shown in Figure 3.3.3B. The chemosensitive cells tend to have crosslinks more than the
chemoresistant cell post cisplatin treatment.
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Figure 3.3.2 Chemoresistant tumor cells are refractory to the formation of cisplatininduced DNA crosslinks. Modified comet assays (single cell gel electrophoresis) was used
to measure interstrand cross-link (ICL) formation and repair. Cells were treated with
cisplatin for 1 h at 100 µM and then placed in drug free media for different time points.
After cisplatin treatment, DNA damage was induced by 50 µM hydrogen peroxide
treatment, on ice, for 30 min. Data represent mean +/- SEM from three experiments. ****
P< 0.0001.
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Figure 3.3.3A Quantification of platinum in DNA using ICP-MS in chemoresistant
and chemosensitive ovarian cancer cells. Cells were treated with cisplatin for 1 h with
100 µM and then placed in drug free media for different time points. DNA was then
isolated, and samples were directly analyzed by ICP-MS. Data represent mean +/- SEM
from three experiments. **** P< 0.0001.
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Figure 3.3.3B Formation of DNA crosslinks and repair in ovarian tumor cells
measured by ELISA. Cells were treated with cisplatin for 1 h (100 µM) and DNA was
isolated at different time intervals (0, 6, 12, 18, and 24 h). Primary Ab (1:250, 0.004
mg/mL), and secondary Ab (1:5000, 0.16 µg/mL) were used. Data represent mean +/- SEM
of 3 replicates
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3.3.4 Both cells and nucleoid bodies from chemoresistant cells are refractory to
crosslinks formation.
The crosslink formation was assessed by the alkaline comet assay and was used to study
the role of nuclear organization on DNA damage formation, through comparison of
response in nucleoid bodies and intact cells. As Figure 3.3.4 shows, the results
demonstrated the same rank order of dose-response in nucleoid bodies as in intact cells,
but with chemoresistant cells being considerably more resistant to damage formation, at all
doses cisplatin.
In intact cells, the chemoresistant cells (SKOV3) showed a lower percentage of DNA
crosslinks compared to the chemosensitive cell lines (A2780 and OCI-P5X) with
increasing concentrations of cisplatin. The percentage of DNA crosslinks in SKOV3 was
around 19 % (*** P < 0.001) following treatment with the highest concentration of
cisplatin, while the percentage of DNA crosslinks in A2780 and OCI-P5X was 33 % and
31 %, respectively at the same concentration of cisplatin.
Moreover, the results showed a similar rank order of dose-response in nucleoid bodies as
in intact cells. Correspondingly, SKOV3 had low percentages of DNA crosslinks with
increasing concentrations of cisplatin comparing to A2780 and OCI-P5X. At the highest
dose of cisplatin, SKOV3 showed a significantly lower percentage 37 % of DNA crosslinks
(*** P < 0.001) compared to A2780 64 % and OCI-P5X 58.67 %.
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Figure 3.3.4 The differential response to cisplatin treatment derives from proportion
associated with the nucleoid body. DNA crosslink formation was determined by variant
of the comet assay in cisplatin treated cells or nucleoid bodies. Data represent mean +/SEM from three experiments. The stars represent the statistical analysis comparing to the
chemosensitive cell lines. **** P < 0.0001, *** P < 0.001, ** P < 0.01.
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3.3.5 Optimization of PI concentration
The staining step is a critical step in the comet assay; therefore, it was important to optimize
the PI concentration to increase the accuracy of the software for having a better detection
during capturing the comets. During this experiment, increase concentrations of the PI were
used, as shown in Figure 3.3.5; and the optimum concentration of PI was 2.5 µg/mL. There
was no significant difference among all the concentrations following the exposure with
different doses of UVB; however, using higher concentrations showed some issues of
detecting the comets. As shown in the Figure 3.3.6, (A-B) software partially recognizes
comets with using a high concentration of PI 3.5 and 4.0 µg/mL following the exposure to
0.5 J/cm2; (C-D) comets display intense brightness more difficult to differentiate nucleus
with using a high concentration of PI 3.5 and 4.0 µg/mL following the exposure to 1.0
J/cm2
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Figure 3.3.5 Levels of DNA damage in HaCaTs irradiated with UVB determined by
alkaline comet assay. Cells were irradiated with 0.5 J/cm2 or 1.0 J/cm2 UVB on ice prior
to undergoing alkaline comet assay and stained with various concentrations of P.I. to assess
% tail DNA. Data represent the mean +/- SEM from three experiments. **** p < 0.0001
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Figure 3.3.6 Potential limitation of using high concentrations of P.I. Cells were
irradiated with 0.5 J/cm2 or 1.0 J/cm2 UVB on ice prior to undergoing alkaline comet assay.
Cells were stained with high concentration of P.I (3.5, 4.0 µg/mL) to examine the ability
of Comet Assay VI software to detect the DNA damage. (A-B) software partially
recognizes comets with using high concentration of PI 3.5 and 4.0 µg/mL following the
exposure to 0.5 J/cm2; (C-D) comets display intense brightness more difficult to
differentiate nucleus with using high concentration of PI 3.5 and 4.0 µg/mL following the
exposure to 1.0 J/cm2
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3.3.7 Optimization of hOGG1 concentration for ovarian cell lines
The optimum conditions for hOGG1 enzyme required to be determined for the ovarian
cancer cell lines. The results in Figure 3.3.7 demonstrated that the level of DNA damage
was increased with the increased concentrations of hOGG1 enzyme. Treatment with
increased concentrations of H2O2 led to a significant increase in levels of oxidized purine
(P < 0.0001) and SB/ALS (P < 0.0001) for the chemosensitive and chemoresistant cell
lines. As shown in Figure 3.3.7, treatment with hOGG1 enzyme led to a significant increase
in levels of oxidized purine and SB/ALS in all ovarian cell lines. The optimum
concentration of hOGG1 enzyme was 4.0 U/mL and was used for the detection of the
oxidized purine induced on the DNA of ovarian cell lines. Control samples which were not
irradiated and were incubated with the same concentrations of hOGG1 enzyme showed no
significant difference following the treatment. Moreover, the amount of oxidized purine
and SB/ALS were assessed using the modified comet assay at each concentration of the
enzyme. It was observed high amounts of oxidized purine at 4.0 U/mL and 8.0 U/mL in
the ovarian cancer cell lines.
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Figure 3.3.7 Induction of DNA breaks and the amount of 8-oxodG in A2780 and
SKOV-3 following treatment with H2O2 (50 µM) determined by hOGG1-modified
comet assay. Cells were treated with increased concentration hOGG1 enzyme (0, 0.4, 0.8,
1.6, 4.0, 8.0 U/mL). The control samples were not treated with H2O2.
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3.3.8 Equivalent BER ability occurs in chemosensitive and chemoresistant ovarian
tumor cells
The hOGG1-modified comet assay was carried out to assess the kinetics of BER after
hydrogen peroxide treatment. The remaining percentage of tail DNA was detected at
different time points. As Figure 3.3.8 shows, the amount of DNA damage remaining for
all cells at the 1 h post treatment was around 30 %. This level was decreased below 25 %
at 2 h post treatment for all cell lines. At 6 h post the treatment, all cell lines showed a
major decline of the amount of DNA damage remaining. This result shows the complete
repair of DNA damage produced by hydrogen peroxide treatment. The data showed that
no significant differences in BER were noted among all the cell lines.
Moreover, all cell lines had increased levels of oxidized purine and SB/ALS at the first
three time points post treatment, Figure 3.3.9. Treatment with 50 µM of H2O2 led to a
significant increase in levels of oxidized purine (P < 0.0001) and SB/ALS (P < 0.0001) for
A2780 at 0 h post treatment, comparing to the control. These levels significantly declined
after 6 h post treatment in the same cell line as shown in Figure 3.3.9A; however, the levels
of oxidized purine and SB/ALS at these time points (1 h, 2 h, and 6 h post treatment) were
still high and significantly different from the control.
Similarly, OCIP5X and SKOV3 had increased levels of oxidized purines (P < 0.0001) and
SB/ALS (P < 0.0001) at 0 h post treatment, comparing to the control. These levels were
also significantly declined at 1 h and 2 h post treatment in the same cell line, however,
these levels were still high and significantly different from the control. Moreover, OCIP5X
and SKOV3 completely repaired all oxidized purines after 6 h, but A2780 were fully repaid
after 24 h., as demonstrated in Figure 3.3.9.
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Figure 3.3.8 kinetics of BER of oxidized purines (A) (+ hOGG1) and repair of strand
breaks (B) (- hOGG1) does not differ between chemosensitive and chemoresistant
ovarian cells. Following 50 µM H2O2 treatment for 30 min, on ice, cells left, in the
incubator, to repair for different times (0 h, 1 h, 2 h, 6 h, 12 h or 24 h). Data represent mean
+/- SEM from three experiments. Statistical analysis was used to compare every individual
cell line, at each point, to their background level, in present or absent of hOGG1. **** P <
0.0001. Background levels were detected as follow; A2780 (9.08 %), OCI-P5x (12.11%),
and SKOV3 (11.67 %)
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Figure 3.3.9 Significant levels of oxidized purines + SB/ALS were induced by H2O2 in
ovarian cancer cells. BER ability does not variety between sensitive and resistant ovarian
cells. Following 50 µM H2O2 treatment for 30 min, on ice, cells left, in the incubator, to
repair for different times (0 h, 1 h, 2 h, 6 h, 12 h or 24 h). Data represent mean +/- SEM
from three experiments. (A) Chemosensitive cell line, A2780; (B) Chemosensitive cell
line, OCIP5X; (C) Chemoresistant cell line, SKOV3.
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3.3.9 UVB dose response
The comet assay was carried out to measure the level of DNA damage induced by different
doses of UVB, as shown in Figure 3.3.10. Exposure to different doses of UVB led to a
significant increase in levels of DNA damage, which were represented as % tail DNA.
Treatment with T4endoV enzyme led to a significant increase in levels of CPD and
SB/ALS in all ovarian cancer cell lines.
As Figure 3.3.10 shows, A2780 cells showed slightly higher DNA damage levels
(SB/ALS) comparing to other cell lines; at 0.25 J/cm2 had 38.66 % while, OCI-P5x showed
34.12% and 32.12% was the level of damage level detected in SKOV3. Following exposure
to 0.5 J/cm2, A2780 had 49.28 % of DNA damage, while OCIP5x showed 48.99 %, and
the chemoresistant cells, SKOV3, had 45.25 % of DNA damage. These percentages were
increased using the T4endoV enzyme which indicated the amount of the CPD following
the exposure to the UVB. The amount of CPD in A2780 following the exposure to 0.5
J/cm2 was 13.66 %, while the amount of CPD in OCI-P5X was 11.13 %. The
chemoresistant cell line had 11.93 % of CPD levels following exposure to UVB. The
optimum UVB dose, to use in the other experiments, was 0.5 J/cm2. The pictures of the
comets representing the DNA damage levels in ovarian cancer cells, following the
exposure to 0.5 J/cm2 UVB, were represented in Figure 3.3.11.
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Figure 3.3.10 Induction of DNA breaks in ovarian cancer cells following the exposure
to UVB. Induction of DNA breaks were measured, following UVB exposure (0.25 and 0.5
J/cm2), by T4endoV-modified comet assay. Data represent mean +/- SEM from three
experiments (100 individual determinations each).
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Figure 3.3.11 Representation of comet pictures of DNA damage following the
exposure to UVB in ovarian cancer cells. Cells were irradiated with 0.5 J/cm2 UVB on
ice prior to undergoing alkaline comet assay, and the indication of of DNA breaks were
then measured. Example of comet images using comet assay IV software. (A-C) After the
UVB exposure, DNA strand breaks allowed the migration of the DNA (under
electrophoresis) away from the nucleoid body something along these lines, whereas in (BD) control had minimal levels of DNA strand breaks, so the DNA remains complexed with
the nucleoid body.
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3.3.10 UVC dose response
The comet assay was carried out to measure the level of DNA damage induced by different
doses of UVB, as shown in Figure 3.3.12. Exposure to different doses of UVC led to a
significant increase in levels of DNA damage, comparing to the control, in all ovarian
cancer cells. Following the exposure to 0.025 J/cm2 UVC, a significant increase levels
DNA damage (around 25 %) was noted in all cell lines. The percentage of tail DNA was
the damage parameter used to illustrate the level of the DNA damage. Following the
exposure to 0.05 J/cm2 UVC, SKOV-3 showed significant resistance to DNA damage
comparing to the chemosensitive cell lines (p < 0.001). At dose of 0.1 J/cm2 UVC, SKOV3 also showed a slight resistance to DNA damage when compared to the chemosensitive
cell lines.
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Figure 3.3.12 Induction of DNA damage in ovarian cancer cells following exposure to
UVC. Cells were UVC exposed, on ice, and then processed for alkaline comet assay. Data
illustrate the mean +/- SEM from three independent experiments. Mann Whitney test was
used to compare the chemoresistant cell line, SKOV-3, to the chemosensitive cell lines.
The stars represent the statistical analysis. *** P < 0.001, * P < 0.05.
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3.3.11 Optimization of T4endoV concentration for ovarian cell lines
During the optimization of T4endoV concentration for the NER assay it was noted that
incubation of SKOV3 cells with the enzyme at concentrations typically used in the
T4endoV modified comet assay, led to the formation of higher comets compared to the
control. Figure 3.3.13A shows that increasing dilution of the T4endoV leads to the
formation of fewer comets in UVB irritated cells. In contrast, no comets are formed by
incubation with T4endoV at any concentration in unirradiated cells. This phenomenon was
also noted for A2780 (Figure 3.3.13B). This finding led us to speculate that the bottle of
T4endoV that we had received was highly concentrated or did not represent the U/μL
stated. Support for this hypothesis came from the experiments which showed we needed to
further dilute the enzyme, to levels unreported in the literature to be effective, and
demonstrated the expected results based upon past experiments in our laboratory (Figure
3.3.14). Again, unirradiated cells showed no increase in comet tail when incubated with
T4endoV (Figure 3.3.14B); however, irritated cells showed a significant increase in % tail
DNA when incubated in the absence of T4endoV (Figure 3.3.14A). Treatment with a low
concentration of T4endoV (0.0001 U/μL) increased the levels of DNA damage, as shown
in Figure 3.3.14B.
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Figure 3.3.13 Damaged comet images from SKOV-3 and A2780 cells following the
treatment with different concentrations of T4endoV enzyme. Ovarian cancer cells were
exposed to 0.5 J/cm2 of UVB and cell were then processed using the T4endoV-modified
comet assay. This experiment was repeated three times and these concentrations were
rapturing the comets in every individual experiment.
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Figure 3.3.14 Typical comet images from SKOV-3 cells following the treatment with
the optimum concentration of T4endoV for removal of CPD from ovarian cells.
Ovarian cells were exposed to 0.5 J/cm2 with 0.5 J/cm2 of UVB and cell were then
processed using the T4endoV-modified comet assay.
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3.3.12 NER repair of UV radiation-induced CPD in ovarian cells

The T4endoV-modified comet assay was performed to measure the kinetics of NER
following the UVB irradiation. As shown in Figure 3.3.15, the remaining percentage of tail
DNA was detected at different time points. The amount of DNA damage remaining at 1 h
and 2 h post irradiation was around 95 % in all ovarian cancer cells. At 6 h post irradiation,
all cell lines showed a slight decline in the amount of DNA damage remaining, around 80
%. Moreover, the amount of CPD and SB/ALS was also determined at each time point, as
shown in Figure 3.3.16. Exposure to 0.5 J/cm2 of UVB led to a significant increase in levels
of CPD (p < 0.0001) and SB/ALS (p < 0.0001) for all the cell lines at all time points,
compared to the control. These levels remainedsignificantlywere remind significantly high
and not fully repaired even at 30 h post irradiation, as shown in Figure 3.3.15 and 3.3.16.
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(A)

(B)

Figure 3.3.15 kinetics of nucleotide repair of CPD (+ T4endoV) and strand breaks (T4endoV) in ovarian cancer cells. Ovarian cells were exposed to 0.5 J/cm2 of UVB and
allowed to repair in the incubator for different time points (0, 1, 2, 6, 12, 24, or 30 h). The
control samples were not irradiated. (A) The percentage of amount of DNA damage
remaining in ovarian cancer cells following the treatment of T4endoV enzyme (0.0001
U/μL). (B) The percentage of amount of DNA damage remaining in ovarian cancer cells
in the absent of T4endoV enzyme; Data represent mean +/- SEM from three experiments.
Statistical analysis was used to compare every individual cell line, at each point, to their
background level, in present or absent of T4endoV. **** P < 0.0001. Background levels
were detected as follow; A2780 (6.18 %), OCI-P5x (5.86%), and SKOV3 (7.13 %).
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Figure 3.3.16 significant levels of CPD + SB/ALS were induced by UVB in ovarian
cancer cells. Repair of the CPD in ovarian cells measured by the T4endoV-modified comet
assay. Cells were exposed to 0.5 J/cm2 of UVB and allowed to repair in the incubator for
different time points (0, 1, 2, 6, 12, 24, or 30 h). The control samples were not irradiated.
(A) Chemosensitive cell line, A2780; (B) Chemosensitive cell line, OCIP5X; (C)
Chemoresistant cell line, SKOV3. Data represent mean +/- SEM from three experiments.
**** P < 0.0001
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3.3.13 Examination of ovarian cancer cells response to environmental and chemical
agents
The comet assay was carried out to measure the level of DNA damage induced by different
doses

of

cisplatin

and

formaldehyde.

Following

the

treatment

with

the

cisplatin/formaldehyde, cells were exposed to 0.5 J/cm2 UVB to induce DNA damage. In
the absence of cisplatin/formaldehyde, the DNA breaks migrate with the current forming
the comet shape. However, in the presence of the treatment the tail becomes shorter as a
result of the formation of crosslinks. As Figure 3.3.17, the control samples showed a low
level of DNA damage (below 5 %). All ovarian cancer cells showed a significant reduction
(p < 0.0001) in % tail DNA following the treatment with cisplatin or formaldehyde,
compared to irritated damaged cells (UVB only). Following cisplatin treatment, a reduction
in DNA damage levels was demonstrated with the increase of cisplatin concentrations in
all ovarian cancer cells, Figure 3.3.17. Cisplatin was more effective in the chemosensitive
cells with increased dosage compared to the formaldehyde; while the chemoresistant cells
are more resistant to form DNA crosslinks following the treatment with
cisplatin/formaldehyde. The reduction of DNA damage induced by cisplatin treatment
were significantly different (p < 0.0001) in A2780 than formaldehyde treatment, as shown
in Figure 3.3.17A. Likewise, this finding was also noted in OCIP5X following the
treatment with 50 µM and 100 µM. of cisplatin the DNA damage level were significantly
reduced comparing to formaldehyde treatment, Figure 3.3.17B. Following the treatment
with 50 µM of cisplatin/formaldehyde, the chemoresistant cells showed less reduction of
DNA damage levels (p < 0.05) which indicated less DNA crosslinks formed comparing to
the chemosensitive cells, Figure 3.3.17C.
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Figure 3.3.17 Chemoresistant cells are more resistant to ICL formation from cisplatin
+ formaldehyde, a representation environmental crosslinks agent. Induction of DNA
damage following the treatment with increase concentration of formaldehyde/cisplatin.
Data represent mean +/- SEM from three experiments. Exposure to UVB was used to
induce the damage
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3.4 Discussion
A growing number of women around the world are getting diagnosed with ovarian cancers
every year. Unfortunately, most of these cancer patients are usually not identified until
related complications are already developed. Generally, there is only an approximated five
years of survival with even less than a 50% chance of favorable outcome. Cisplatin is
considered as a very dynamic medication for the treatment of ovarian disease throughout
the past forty years, and the medical findings for female patients with malignant ovarian
growth can be characterized by the tumor reaction to cisplatin. The results of this chapter
demonstrated a clear observation of the molecular differences between the chemosensitive
and chemoresistant cells. Chemoresistant cells have a significantly higher cell survival in
response to cisplatin compared to chemosensitive cell lines. This suggests that
chemoresistant cells could have a mechanism that helps to tolerate cisplatin chemotherapy.
Unhooking the formed crosslinks could be one of the strategies to reduce the cisplatin
affects. Chemoresistant tumor cells are refractory to the formation of cisplatin-induced
DNA crosslinks. It was noticed that SKOV 3 had a low percentage of ICL following
cisplatin treatment comparing to the chemosensitive cell lines. This result was conducted
by modified comet assays were used to measure ICL formation. Further approaches, ICPMS and ELISA, were used to confirm that SKOV3 was more resistant to the ICL formation
following cisplatin treatment compared to the chemosensitive cells, as demonstrated in
Figure 3.3.2 and 3.3.3. The formation of cisplatin-DNA adducts, in the chemosensitive and
chemoresistant cells, was measured by determining the platinum concentration in DNA
with ICP-MS and by using anti-cisplatin-DNA with ELISA. This can lead to understanding
the mechanisms of drug-DNA interactions in ovarian cancer cells. One of the major defects
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that accompany cisplatin use in treating cancer is the development associated with drug
resistance, which was correlated with a reduced intracellular accumulation of cisplatin.
Therefore, the intracellular platinum concentration can be used as an indicator of the
resistance of cisplatin.
Additional theories that may be involved in the development of chemoresistance is the
effectiveness of the repair systems in the cell lines. Therefore, studying the repair kinetics
was essential. Equivalent BER ability occurs in chemosensitive and chemoresistant ovarian
tumor cells were demonstrated; however, significant levels of oxidized purines + SB/ALS
were observed in ovarian cancer cells, Figure 3.3.9. Moreover, the kinetics of nucleotide
repair of CPD and strand breaks in ovarian cancer cells were conducted. Interestingly, it
was noticed that exposure to 0.5 J/cm2 of UVB led to a significant increase in levels of
CPD and SB/ALS for all the cell lines at all time points. These levels remained significantly
high and were not fully repaired even at 30 h post-irradiation.
Generally, cisplatin is an effective chemotherapeutic agent that induces DNA damage;
however, it is less effective with the inference of the process of DNA repair systems. Some
of the processes involved in the repair process include NER, MMR, HR, FA pathway,
NHEJ, and BER. Therefore, further investigations are needed in order to have a better
understanding of the repair system involvement in the chemoresistance (reviewed in
section 1.4).
Principally, the key mechanism to cisplatin activity is the formation of DNA crosslinks,
which interrupts the proper functioning of cellular DNA, which subsequently induces
apoptosis. Therefore, investigating the response of ovarian cancer cells to different
crosslinking agents was essential in this study. As Figure 3.3.17 shows, chemoresistant
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cells are more resistant to ICL formation from cisplatin and formaldehyde, a representative
environmental crosslinking agent. Based on the previous findings, and the response to the
environmental crosslinking agent, the assumption that chemoresistant cells have a
mechanism to resist the formation of crosslinks was developed. Therefore, further
investigations were required to have a better understanding of the chemoresistance. One of
the novel approaches used was to study the DNA damage response in different cell
substrates. This approach investigated the basis of this differential DNA damage response
by examining the potential role of nuclear organization, via the comparison of damage
induction in nucleoid bodies versus intact cells. The results demonstrated the same rank
order of dose-response in nucleoid bodies as observed in intact cells, with chemoresistant
cells being considerably more resistant to damage formation, at all doses of cisplatin. These
data provide a basis for further studies to improve our understanding of the differential
DNA damage response associated with chemosensitive and chemoresistant ovarian cells.
Therefore, isolation and characterization of associated nuclear proteins in ovarian cancer
cells and study their involvement in the chemoresistance is one of the future directions for
this thesis.
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CHAPTER 4
EVALUATION OF GENE POSITIONING AND COPY NUMBER CHANGES IN
CHEMOSENSITIVE AND CHEMORESISTANT OVARIAN CANCER CELL
LINES
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4.1 Introduction
Ovarian cancer is the leading cause of gynecologic cancer-related deaths among women.
This cancer rarely has specific symptoms making early detection challenging, and there are
limited chemotherapeutic options, with many patients developing resistance to treatment,
eventually succumbing to the disease. In 2020, an estimated 21,750 women will be
diagnosed with ovarian cancer, and 13,940 women will die from the disease in the US,
according to the American Cancer Society [8]. It is hypothesized that there is a difference
in the organization of chromatin in chemosensitive (CS) and chemoresistant (CR) ovarian
cancer cell lines, and gene repositioning and copy number changes are associated with
resistance to chemotherapy in ovarian cancer cell lines. Basically, genomic organization
applies to the linear order of DNA components and their division into chromosomes. The
human genome is divided into 46 chromosomes, which are packaged in order to fit inside
the nucleus. At the chromosome level, the organization is defined in preferential territories
filled by chromosomes. In eukaryotic cells the genome is highly spatially organized.
Functional relevance of higher order genome organization is implied by the fact that
specific genes, and even whole chromosomes, alter spatial position in concert with
functional changes within the nucleus, for example with modifications to chromatin or
transcription [178].
While global genome organization patterns remain largely conserved in disease, some
genes and chromosomes occupy distinct nuclear positions in diseased cells compared to
their normal counterparts, with the patterns of reorganization differing between diseases.
Importantly, mapping the spatial positioning patterns of specific genomic loci can
distinguish cancerous tissue from benign with high accuracy. Genome positioning is an
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attractive novel biomarker since additional quantitative biomarkers are urgently required
in many cancer types [179]. Therefore, this study was important to investigate the
difference in organization of genes in chemosensitive and chemoresistant cell lines.
Hence, it was essential to investigate whether the exposure to cisplatin chemotherapy is
altering gene positioning; also, to evaluate the copy number changes in ovarian cancer
cells. This study aims to explore the correlation between gene positioning prior to and
following exposure to cisplatin chemotherapy in CS and CR ovarian cancer cell lines. It
well established that chromosomes and genes occupy distinct cell-type-specific and
evolutionarily conserved locations in interphase nuclei. This organization of chromatin in
the nucleus is hypothesized to be additional level of epigenetic regulation of the genome
[178, 181]. The packaging and organization of the genome into discrete chromosome
territories in interphase nuclei is hypothesized to be involved in regulating important
genome functions [178, 181]. In the majority of cell types, gene-rich chromosomes are
preferentially located more towards the nuclear interior, with gene-poor chromosomes
localized toward the nuclear periphery. Additionally, within each cell-type, how the DNA
is packaged within the chromosome territory may differ, with expressed genes often
localized at, or near the periphery of the chromosome territory. The nuclear localization of
chromosome territories and the position of individual genes within individual chromosome
territories likely plays an important role in various genome functions (e.g., gene expression,
DNA damage induction, recognition, and repair etc.). Numerous studies have demonstrated
alterations in the nuclear position of chromosomes and/or genes following altered gene
expression, induction of DNA damage, and in a number of diseases including
laminopathies and cancer [179-184]. Altered chromatin organization is accompanied with
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functional changes such as changes in gene transcription and modifications to chromatin
[179] At present, the regulation of how chromosome and gene positioning is determined in
the nucleus remains to be discovered. However, chromosome and/or gene organization is
increasingly recognized as a potential marker for disease and new diagnostic tool
[179,183]. Altered gene positing may play an important role in the molecular difference
between chemoresistant and chemosensitive ovarian cell lines. In order to study gene
positioning and assess copy number changes, fluorescence in situ Hybridization was used.
FISH is a cytogenetic technique that allows the nuclear localization of target regions to be
established and the detection of chromosomal abnormalities using commercially available
fluorescent probes that bind to DNA with a high degree of sequence complementarity.
As discussed in Foster and Bridge (2005), the spatial and temporal organization of genomes
in their nuclear environment helps to control their function and behavior is becoming
widely accepted, especially when we see genome mis-organization in disease cells such as
cancer and nuclear envelope diseases such as laminopathies [183]. Studies on functional
genome organization should include how the genome interacts with the under-lying
architecture making up the nucleus. Thus, under-standing aspects of the genome and its
interphase home in 4D will lead to 21st century treatments and therapies for a range of ills
from cancer to ageing. In this chapter, FISH was used to map specific genes potentially
involved in cancer formation and/or progression to determine if the targeted genes are
randomly or nonrandomly organized in ovarian cancer cell lines (A2780, OCI-P5X, and
SKOV3). Differences in gene positioning of the selected genes and copy number changes
were evaluated in the two chemosensitive ovarian cell lines (A2780 and OCI-P5X) and the
chemoresistant ovarian cell line (SKOV3) and following exposure to cisplatin
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chemotherapy. It is hypothesized that gene positioning will be non-random for the
investigated genes. Additionally, that gene positioning and gene copy number may differ
between CS and CR ovarian cancer cell lines, and gene positioning may be altered
following cisplatin chemotherapy exposure.
4.2 Methods
4.2.1 Ovarian cancer cell lines
Three ovarian cancer cell lines were used in this study; two cell lines are sensitive to
cisplatin chemotherapy (A2780 and OCI-P5X), and one is resistant (SKOV-3). All cells
were cultured according to the supplier’s recommended media and condition for each cell
line (section 2.2.1 to section 2.2.4). Briefly, all cells were cultured in T25 cell culture flask
and allowed to grow with the manufacturers recommended cell culture media at 37 °C in
a 5% CO2 and humidified atmosphere. For each cell line, two experimental groups were
prepared, one control group (no cisplatin treatment), and the other treated with cisplatin.
4.2.2 Cisplatin treatment
For the treated groups, all investigated cell lines were treated with cisplatin at the same
time when they become confluent enough to perform the treatment (section 2.2.15.1).
Briefly, treated groups were treated with cisplatin (100 µM) for 1 h at 37 °C in a 5% CO2
and humidified atmosphere. Subsequently, the cell culture media containing the cisplatin
was removed and replaced with drug-free media for 12 h at 37 °C in a 5% CO2 and
humidified atmosphere. All groups were then trypsinized and transferred to a 15 mL
centrifuge tubes, which were centrifuged at 9000 rpm for 5 mins. The supernatant was
removed, and the cell pellet was fixed by resuspending the pellet dropwise with a total of
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5 mL of 3:1 methanol: acetic acid. Resuspension of the pellet was performed after each
drop of the fixative to minimize cell clumping. Samples were centrifuged and the fixation
and resuspension step were repeated two further times. Samples were subsequently stored
at – 20 °C until required for experiments.
4.2.3 Dual color FISH
The FISH protocol has been prescribed in detail previously in section 2.2.15.2. Briefly,
following the fixation step from the previous section, the pellet was centrifuged and the
supernatant was removed to 1 – 2 mL depending on the size of the cell pellet. The cell
pellet was then resuspended and 1-5 µL of the cell suspension depending on the pellet size
was placed onto a glass microscope slide. Slides were visualized under a phase contrast
microscope to confirm the optimal cell density (200 - 500 cells not overlapping). Slides
were then washed with PBS and dehydrated in an ethanol series (70%, 80%, and 100%)
for five min each and air-dried. Slides were then washed in ddH2O followed by rinsing in
PBS before incubation in 4% paraformaldehyde/PBS at 4 °C for 10 min; slides were then
rinsed with PBS followed by ddH2O at room temperature, and another ethanol series was
carried out at room temperature for 2 min each and the slides air-dried. FISH probes
complementary to specific genes used in this study are provided in Table 2.2.1. Seventeen
genes were selected to be targeted in this study, genes were selected based on their
involvement in cancer formation and progression, (e.g., known driver mutation, altered
gene expression etc.). The name of the gene, known function and chromosome locations
have been described in detail in Table 4.4.1, FISH probes were either labelled with TRITC
(red) or FITC (green) fluorescent dyes and allowed evaluation of 2 FISH probes
simultaneously. The FISH probe mix of the two different genes and hybridization mix was
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prepared as per the manufacturer’s guidelines. Once mixed the FISH probes were then
vortexed and pulse microfuged and subsequently pre-denatured at 73 °C for 10 min in a
water bath. Following denaturation of the FISH probes in hybridization mix, 1 µL of the
probe was added to the slide, and a 5 mm round coverslip was placed on the slide; and
sealed with rubber cement. The microscope slides with the predenatured FISH probes were
placed in a hybrite (Vysis) at 75 °C, for 90 sec to denature the DNA in conjunction with
the FISH probes. Subsequently, the DNA and FISH probes were allowed to hybridize
overnight (16 h) at 37 °C in a humidified chamber. Once the hybridization period was
completed, the slides were washed in 0.4X SSC-0.3% tween to remove the coverslips at
room temperature. Then, the slides were placed in a pre-warmed solution of 0.4 X SSC0.3% Tween-20 at 73 °C and washed for 90 seconds to remove the excess probe. Slides
were then placed in 2X SSC-0.1% tween for a 1 min wash at room temperature followed
by an ethanol series (2 min each). Finally, slides were air-dried and counterstained with
DAPI to stain all DNA to allow identification of the interphase nucleus. Subsequently,
slides were stored at 4 °C until ready for capturing.
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Table 4.4.1 Descriptive table of all genes used in the study (Gene Cards Human
Gene Database)

Gene

Gene Function

Chromosome
Location

Involved in cell proliferation

1

AKT Serine/Threonine
Kinase 3
(AKT3)
Alpha-1,3

Part of enzyme family that adds glucose

Glucosyltransfrease

residue to necessary proteins to maintain

(ALG8)

11

normal function

B-Raf Proto-Oncogene,
Serine/Threonine Kinase

Regulates a pathway cell division and
7
differentiation

(BRAF)
Breast cancer type 1
Maintains genomic stability; tumor suppressor

17

(BRCA1)
Breast cancer type 1

Maintains genomic stability; tumor suppressor
13

(BRCA2)
Cyclin E1 (CCNE1)

gene, active in HR pathway.

CDK kinase regulating mitotic cycle
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19

Catenin Beta 1

Involved in maintaining growth and adhesions
3

(CTNNB1)

between epithelial cell layers

Folate Receptor 1
Transport folate derivatives into cells

11

Involved in the regulation of cell proliferation

12

(FOLR1)
KRAS Proto-Oncogene
(KRAS)
MDS1 and EVI1 Complex
Locus

Involved in hematopoiesis, apoptosis; and
3
differentiation;

(MECOM)
Nucleus Accumbens

Involved in regulating apoptosis and
19

Associated 2 (NACC1)

proliferation

Neurofibromin 1

Involved in cell communication mainly in
17

(NF1)

regard to growth factors

Paired Box 3
Regulates transcription

2

Tumor suppressor

10

(PAX3)
Phosphatase and Tensin
Homolog (PTEN)
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RB Transcriptional
Corepressor 1

Cell cycle regulator; genomic stabilizer

13

Regulates transcription

8

(RB1)
SRY-Box 17
(SOX17)

Tumor Protein 53

Tumor suppressor protein; regulates
transcription; regulates DNA repair

(TP53)

mechanisms
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4.2.4 FISH image capture
The image capture process is described previously in Section 2.2.15.3. In brief, Slides were
examined on an Olympus BX-61 epifluorescence microscope supplied with a cooled CCD
camera and fluorescence filters for FITC, TRITC, and DAPI. Images were captured using
SmartCapture 3 software. A minimum of 100 individual (non-overlapping) cells were
analyzed per FISH probe, per cell line, per condition (cisplatin treated and untreated).
4.2.5 Assessment of gene copy number
The copy number of each gene was assessed when capturing FISH images. The number of
fluorescent signals (red or green) were scored in each individual cell to assess the copy
number of each gene in each cell, in each cell line and following cisplatin treatment. A
strict scoring criteria was used to assess copy number. All signals had to be similar in size
and intensity and signals had to be at least one signal distance apart to be counted as two
individual signals, (rather than a split signal.
4.2.6 Radial assessment of gene positioning in interphase nuclei
To evaluate the gene positioning in interphase nuclei previously published methodologies
were utilized [180]. Assessment of gene localization within the interphase nucleus was
established using a custom script written for Image J. This script allows for the separation
of each image into the three individual color channels (TRITC [red], FITC [green], which
correspond to the FISH probes and DAPI (blue) for the DNA counterstain). The software
converts the DAPI fluorescence to a binary mask that allows for the creation of five rings
of equal area based on the DAPI fluorescence intensity. The software then measures to
amount of red and green fluorescence corresponding to each targeted gene located in each
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of the five rings (of equal area), relative to the total signal for the area that is covered by
the ring, as shown in Figure 2.2.6 Data is collected and normalized against the different
DNA content (DAPI counterstain) in the nucleus to compensate for the fact that a 3D object
is observed under two-dimensions. The amount of red and green fluorescence in each of
the five rings of equal area can then be displayed in a histogram to display the nuclear
localization of each gene in the 100 cells analyzed per gene, per cell line, per treatment
(control or cisplatin treated).
4.2.7 Assessment of nonrandom gene positioning in interphase nuclei and statistical
analysis
Based on the radial organization software data it is possible to determine the nuclear
localization of the targeted genes within the interphase nuclei. The histograms produced
can indicate whether a gene is preferentially nonrandomly or randomly organized and
where the gene tends to be localized. For example, if more red or green fluorescence is
detected in the inner most rings the gene is more interiorly located, versus peripherally
located if more fluorescence is detected in peripheral rings. In both of these cases, it would
indicate a nonrandom localization of the gene. However, if the red or green fluorescence is
roughly equally distributed in all of the rings it suggests a more random organization.
Whether the nuclear organization of a gene was nonrandomly or randomly organized was
confirmed using the Chi-squared goodness of fit (χ2) (p < 0.05) as per previously published
studies [180, 185]. This statistical test was also utilized to determine whether gene
positioning differed [180, 185] between the CS and CR lines and whether genes were
repositioned following cisplatin treatment within the same cell line.
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4.3 Results
4.3.1 Nonrandom gene positioning in ovarian cancer cell lines
The nuclear localization of 17 different genes (Table 4.4.1) was examined in three ovarian
cancer cell lines (A2780, OCI-P5X, and SKOV3) in control (no cisplatin treatment; Table
4.4.2A) and cisplatin treated cell lines (Table 4.4.2 B). Of the 17 genes tested, eight genes
(47.06%) (ALG8, BRCA1, BRCA2, CNNE1, FOLR1, NACC1, NF1, and TP53)
demonstrated nonrandom organization in all cell lines and in all conditions (cisplatin
treated and untreated).
In the A2780 cell line, 10 genes (58.82%) were found to be nonrandomly organized in the
control untreated cells (additional genes included KRAS and SOX17). In the cisplatin
treated A2780 cells, nine genes (52.94%) were nonrandomly organized. Compared to the
control A2780 cells cisplatin treatment resulted in nonrandom positioning of RB1 and
random positioning of KRAS and SOX17.
In the OCI-P5X cell line, 13 genes (76.47%) were found to be nonrandomly organized in
the control untreated cells (additional genes included CTNNB1, KRAS, PAX3, RB1 and
SOX17). In the cisplatin treated OCI-P5X cells, 15 genes (88.24%) were nonrandomly
organized. Compared to the control OCI-P5X cells cisplatin treatment resulted in
nonrandom positioning of MECOM and PTEN.
In the SKOV3 cell line, 15 genes (88.24%) were found to be nonrandomly organized in
the control untreated cells (additional genes included AKT3, BRAF, CTNNB1, KRAS,
PAX3, RB1 and SOX17). In the cisplatin treated SKOV3 cells, 14 genes (82.35%) were
nonrandomly organized. Compared to the control SKOV3 cells cisplatin treatment resulted
in random positioning of CTNNB1.

128

Between the CS and CR cell lines, two genes (AKT3, and BRAF) were found to be
randomly organized in CS cell lines and nonrandomly organized in the CR cell line in both
control and cisplatin treated cells (Figure 4.4.1).
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Table 4.4.2 Nonrandom gene positioning in control and cisplatin treated A2780,
OCI-P5X, and SKOV3 ovarian cancer cell lines

Table 4.4.2 displays genes found to be statistically significantly nonrandomly positioned
(p=< 0.05; cells shaded blue) in the interphase nucleus of three different ovarian cancer
cell lines without (A) and with cisplatin treatment (B). Genes found to be randomly
organized are indicated by white boxes (p=> 0.05).
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BRAF and AKT3 were randomly organized in CS (A2780/OCIP5X) and non-randomly organized in CR (SKOV3)

Figure 4.4.1 Differences in gene positioning (BRAF/AKT3) between CS and CR ovarian cell lines. Example of data obtained
from 2 different genes (BRAF/AKT3) in the three cell lines. Graphs display percentage of fluorescence for each gene from the nuclear
interior (1) to the nuclear periphery (5) within the three cell lines. Error bars represent the standard error of the mean. Statistically
significant findings p<0.05 * non-random organization untreated cells; * non-random organization cisplatin treated cells.
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KRAS and SOX17 were randomly organized only in CS (A2780)

Figure 4.4.2 KRAS and SOX17 were randomly organized only in A2780. Example of data obtained from 2 different genes
(KRAS/SOX17) in A2780. Graphs display percentage of fluorescence for each gene from the nuclear interior (1) to the nuclear
periphery (5) within the three cell lines. Error bars represent the standard error of the mean. Statistically significant findings p<0.05
* non-random organization untreated cells; * non-random organization cisplatin treated cells.
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RB1 was randomly organized only in CS (A2780)

Figure 4.4.3 RB1 was randomly organized only in A2780. Example of data obtained from one gene (RB1) in A2780. Graphs
display percentage of fluorescence for RB1 from the nuclear interior (1) to the nuclear periphery (5) within the three cell lines. Error
bars represent the standard error of the mean. Statistically significant findings p<0.05 * non-random organization untreated cells; *
non-random organization cisplatin treated cells.
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PAX3 was randomly organized in CS (A2780)

Figure 4.4.4 PAX3 was randomly organized in A2780. Example of data obtained from one gene (PAX3) in A2780. Graphs
display percentage of fluorescence for PAX3 from the nuclear interior (1) to the nuclear periphery (5) within the three cell lines.
Error bars represent the standard error of the mean.
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MECOM and PTEN were randomly organized in CS (A2780/OCIP5X) and CR (SKOV3)

Figure 4.4.5 Differences in gene positioning (MECOM/PTEN) between CS and CR ovarian cell lines. Example of data obtained
from 2 different genes (MECOM/PTEN) in all three cell lines. Graphs display percentage of fluorescence for each gene from the
nuclear interior (1) to the nuclear periphery (5) within the three cell lines. Error bars represent the standard error of the mean.
Statistically significant findings p<0.05 * non-random organization untreated cells; * non-random organization cisplatin treated
cells. # difference in gene positioning between CR and CS cell line
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4.3.2 Differences in the nuclear localization of genes in chemosensitive and
chemoresistant cell lines
In addition to assessing whether the 17 investigated genes displayed random or nonrandom
organization, the nuclear position of each of the genes in the interphase nucleus was
compared between CS and CR cell lines. Differences in the nuclear position of genes
between CS and CR cell lines could potentially be used to predict whether a patient’s
ovarian cancer might be CS or CR which may offer important prognostic information and
potentially alter treatment and or management of the patient. Three genes displayed altered
patterns of nuclear position in at least one CS cell line and the CR cell line. Specifically,
CCNE1 was positioned preferentially toward the nuclear interior in both the CS cell lines
A2780 and OCI-P5X, whereas, in the CR cell line SKOV3 it was positioned more
intermediately in the nucleus (Figure 4.4.6). A difference in the nuclear of FOLR1 was also
observed between A2780 and SKOV3, with the gene being much more interior in SKOV3
versus A2780. However, this gene in OCI-P5X was not found to be significantly differently
positioned than in SKOV3 displaying a position in between that found in the A2780 and
OCI-P5X cell line (Figure 4.4.7). A significant difference in the position of the NF1 gene
was also observed between the OCI-P5X cell line and SKOV3, but no difference was
observed for A2780 cell line. With the NFI gene being positioned more toward the nuclear
interior in the SKOV3 cell line versus the OCI-P5X cell line (Figure 4.4.8).

136

Figure 4.4.6 Differences in gene positioning (CCNE1) between CS and CR ovarian cell lines. Example of data obtained from
CCNE1 in all three cell lines. Graphs display percentage of fluorescence for the gene from the nuclear interior (1) to the nuclear
periphery (5) within the three cell lines. Error bars represent the standard error of the mean. Statistically significant findings p<0.05
* non-random organization # difference in gene positioning between CR and CS cell line
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Figure 4.4.7 Differences in gene positioning (FOLR1) between CS and CR ovarian cell lines. Example of data obtained from
FOLR1 in all three cell lines. Graphs display percentage of fluorescence for the gene from the nuclear interior (1) to the nuclear
periphery (5) within the three cell lines. Error bars represent the standard error of the mean. Statistically significant findings p<0.05
* non-random organization. # difference in gene positioning between CR and CS cell line
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Figure 4.4.8 Differences in gene positioning (NF1) between CS and CR ovarian cell lines. Example of data obtained from NF1
in all three cell lines. Graphs display percentage of fluorescence for the gene from the nuclear interior (1) to the nuclear periphery
(5) within the three cell lines. Error bars represent the standard error of the mean. Statistically significant findings p<0.05 * nonrandom organization. # difference in gene positioning between CR and CS cell line
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4.3.3 Copy number changes in chemoresistant and chemosensitive cell lines.
The use of FISH also allowed verification of the copy number of each of the 17 investigated
genes in each of the three investigated cell lines (Figure 4.4.6). The average copy number
observed in each gene is presented in (Figure 4.4.7 to Figure 4.4.9). In the normal situation,
it would be expected that each cell would contain two (diploid) copies of each gene. This
is largely the case for the CS cell line A2780 for all investigated genes (Figure 4.4.7). The
other two cell lines had a more heterogeneous population in terms of copy number changes.
The expected diploid copy number was observed for the following genes: AKT3, BRCA1,
BRCA2, BRAF, CTNNB1, and PTEN in the CS cell line OCI-P5X, with RB1, and NF1
displaying slightly less than the expected two signals. The remaining genes displayed
greater than the expected signals (Figure 4.4.8 and Figure 4.4.9). However, the CR SKOV3
cell line exhibited significant copy number changes with the exception of PTEN and TP53
(Figure 4.4.9). Statistical analysis was performed using GraphPad Prism. The copy number
changes were analyzed using non-parametric t-tests (Mann Whitney) to compare the values
between the groups. The results are represented as mean ± SEM.
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Figure 4.4.9 The highest increase in copy number was observed in CR cell line SKOV-3. Chemoresistant cell line shows abnormal
numbers of copies of the NF1 gene (green signals) compared to the chemosensitive cell lines. The expected diploid number in healthy
cells is two copies. Up to 8 copies were found in the chemoresistant cells, SKOV-3. A minimum of 100 cells were captured and analyzed
per gene per cell type. commercially available fluorescent probes that bind to DNA with a high degree of sequence complementarity to
NF1 only were used.
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Figure 4.4.10 There was a significantly increased copy number observed in CR cell
line (SKOV3) compared to the CS (A2780 and OCIP5X). SKOV3 showed a higher
average ploidy in BRCA11, BRCA2, BRAF, KRAS, MECOM, and RB1. A minimum of
100 cells were captured and analyzed per gene per cell type for every experiment. The
copy number changes were analyzed using non-parametric t-tests (Mann Whitney) to
compare the values between the groups. The results are represented as mean ± SEM.
**** P< 0.0001
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Figure 4.4.11There was a significantly increased copy number observed in CR cell
line (SKOV3) compared to the CS (A2780 and OCIP5X). SKOV3 showed a higher
average ploidy of NF1, NACC1, CCNE1, PAX3, SOX17, and FOLR1. A minimum of 100
cells were captured and analyzed per gene per cell type for every experiment. The copy
number changes were analyzed using non-parametric t-tests (Mann Whitney) to compare
the values between the groups. The results are represented as mean ± SEM. **** P< 0.0001
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Figure 4.4.12 There was a significantly increased copy number observed in CR cell
line (SKOV3) compared to the CS (A2780 and OCIP5X). SKOV3 showed a higher
average ploidy of AKT3, PTEN, and CTNNB1. There were no significant differences
observed between SKOV3 and OCIP5X in ALG8 and TP53 genes. A minimum of 100 cells
were captured and analyzed per gene per cell type for every experiment. The copy number
changes were analyzed using non-parametric t-tests (Mann Whitney) to compare the values
between the groups. The results are represented as mean ± SEM. **** P< 0.0001

144

4.0 Discussion
The aim of this study was to evaluate the nuclear organization of genes selected due to their
involvement in cancer formation and progression. Seventeen genes were studied, and the
nuclear position of these genes was evaluated in three ovarian cancer cell lines, two
sensitive to cisplatin chemotherapy (A2780 and OCIP5X) and one chemoresistant
(SKOV3). Additionally, the nuclear organization of the targeted genes was evaluated in
the three cell lines following cisplatin treatment (treated) and without cisplatin treatment
(control), to establish whether exposure to the chemotherapeutic agent was able to induce
changes in the nuclear organization of the tested genes. The nuclear position was evaluated
using a widely used approach that assesses the 2D radial distribution of FISH probes within
the nucleus [186]. The chi-squared goodness-of-fit statistical analysis was utilized to
examine differences in the radial distribution of the genes to determine whether genes were
randomly or nonrandomly organized and whether there were significant differences in gene
positioning between the different cell lines. Several genes showed nonrandom organization
in all cell lines in the presence of absent of cisplatin treatment; ALG8, BRCA1, BRCA2,
CNNE1, FOLR1, NACC1, NF1, and TP53. In terms of nonrandom versus random
organization in the control (untreated) cell lines the A2780 cell line showed the highest
number of genes to be randomly organized (7 out of 17; 41.18%), followed by OCI-P5X
(4 out of 17; 23.53%) and SKOV3 (2/17; 11.76%). When comparing nonrandom versus
random organization in the cisplatin treated cell lines, small changes were observed for a
handful of genes in all cell lines. These changes included several genes that were
nonrandomly organized in control cells becoming randomly organized following cisplatin
treatment and vice versa. These results demonstrate that the majority of genes tested
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display nonrandom organization, however the number of genes that were nonrandomly
organized varied between cell lines. Moreover, evidence was provided to suggest that
cisplatin treatment has the ability to potentially alter the gene positioning observed in
control cell lines. Moreover, AKT3, and BRAF were found to be randomly organized in CS
cell lines and nonrandomly organized in the CR cell line in both control and cisplatin
treated cells, suggesting that the organization pattern of these genes may be useful to
differentiate between CS and CR tumors. However, clearly more work is needed to confirm
these findings.
To have better understanding about chemoresistance, the nuclear positioning of genes was
compared to determine if any genes displayed a significant difference in gene positioning
between CR (SKOV3) and CS cell lines. The gene CNNE1 showed a significant difference
in nuclear position in both CS cell lines A2780 and OCI-P5X compared to SKOV3.
Additionally, two genes FOLR1 and NF1 showed a difference in organization between one
of the CS cell lines and the CR SKOV3 cell line, specifically A2780 (FOLR1) and OCIP5X (NF1). These results suggest that it may be possible to identify genes that occupy
different positions in CS and CR cells for example CNNE1 as shown in this study. These
results provide pilot data that suggest it may be possible identify individual genes that could
provide valuable diagnostic and prognostic information for patients with ovarian cancer,
to determine whether their tumors are CS or CR. These findings need to be confirmed in
future studies with additional cell lines, genes and patient tumor samples.
Interestingly, the chemoresistant cell line showed abnormal increases in copy number
changes for many genes compared to the chemosensitive cell lines. Up to 8 copies of NF1
were demonstrated, as shown Figure 4.4.6, while an average of two copies were found in
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the chemosensitive cell lines. This finding of altered and increased copy number was also
demonstrated for the majority of the seventeen genes, Figure 4.4.9. The expected diploid
copy number was observed for the majority of the 17 investigated genes in the A2780 cell
line, whereas the OCI-P5X cell line had a little more variation in the copy number of certain
genes but significantly less than the CR SKOV3 cell line. Two genes, ALG8 and TP53
were not significantly different in SKOV3 and OCIP5X.This study provides evidence of
non-random gene positioning in both sensitive and resistant ovarian cancer cell lines. The
chemosensitive cells, A2780, was the most well controlled as it is almost perfectly diploid
(Figure 4.4.9). Both of the CS cell lines were more likely to be diploid than the CR cell
line, OCI-P5X averages to just above diploid.
These results suggest that for the investigated genes the SKOV3 CR cell line has
significantly more accumulated mutations as measured by copy number changes compared
to the CS cell lines.
Furthermore, the chemoresistant cell line has an abnormal increase in copy number,
compared to A2780 or OCI-P5X, the two sensitive cell lines. Chromosome aneuploidy and
copy number changes are consistently observed in most cancers [182,187,188]. It has been
observed in different types of cancer the increasing aneuploidy and copy number changes,
which could be associated with the chemoresistance [187]. These factors, increasing
aneuploidy and copy number changes, were observed; however, further investigation
required to approve the causation of the chemoresistance. It has been reported that copy
number changes are often increased in aggressive tumors. [184, 189, 190, 191, 192].
There was a small decrease in the organization of genes in the cisplatin treated cell lines,
as presented in Table 4.4.2. However, this could be as result of the duration of cisplatin
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treatment; therefore, a time course would be one of the future directions of this study.
Furthermore, future research should give repeated chemotherapy treatment to cells and
continuously check the location to see if genes reorganize. Further investigations should
use cancer cells with the similar characters of A2780, OCI-P5X, and SKOV3 to fully
understand the real difference in response to the treatment. Therefore, A2780cis, the parent
cisplatin-sensitive A2780 cell line, will be used to study the gene repositioning in the
presence and absence of cisplatin. Importantly, this study will provide informative data that
will help to provide a better understanding about cisplatin chemoresistance. These findings
suggest that that it may be possible to utilize gene positioning as a novel diagnostic and
prognostic tool in ovarian cancer that may be able to differentiate between CS and CR
tumors. If future studies confirm and expand these findings, they may ultimately lead to
better patient counseling and altered patient management which may lead to better patient
outcomes.
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CHAPTER 5
CONCLUSION AND DIRECTIONS FOR FUTURE RESEARCH
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5.1 Conclusion
This thesis aimed to investigate DNA damage and genomic organization in the cellular
response to platinum chemotherapy in ovarian cancer cell lines. The outcomes from this
thesis distinguished the DNA damage response and repair in chemoresistant and
chemosensitive ovarian cell lines. The DNA crosslink formations were evaluated between
the chemosensitive and chemoresistant cells following the cisplatin chemotherapy.
Moreover, in this dissertation, the evaluation of gene positioning and copy number changes
in chemosensitive and chemoresistant ovarian cancer cell lines were conducted. The
outcome indicated differences in the nuclear position of potential genes between
chemosensitive and chemoresistant. The results also demonstrated copy number changes,
which tended to be abnormal in chemoresistant cells compared to the chemoresistant cell
lines.
Consequently, this thesis's future directions will help to understand the chemoresistance in
ovarian cancer cells better. However, further investigations are needed to distinguish the
foundation of chemoresistance fully. There is a requirement to develop novel strategies for
ovarian cancer treatment. Perhaps the most remarkable contributions to understanding this
phenomenon at a cellular level are the development of various macromolecules, for
example, DNA, messenger RNA, and proteins, to evaluate the response of ovarian cancer
to chemotherapy.
5.2 Directions for future research
By providing a foundation of cisplatin and the molecular basis of chemoresistance in
ovarian cancer, further investigations are needed to understand better how ovarian cancer
cells acquire chemoresistance. This dissertation's results are intended to open the way for
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different strategies for further investigations of cisplatin and the molecular basis of
chemoresistance. In this study, different approaches have been initiated and used to
introduce the next phase of this project. There are three main directions to achieve: (1)
Isolation and characterization of nuclear associated proteins in ovarian cancer cells and
study their involvement in the chemoresistance. (2) Investigation of factors that can
enhance the chemotherapy treatment's effectiveness, like 8-TrzdG and 8-TrzdA, which
were reported to be beneficial [175] and [176]. (3) To identify regions of the genome in
which preferential repair of, and/or resistance to DNA damage results in gene “drivers” of
chemoresistance. Identifying the regions will help to find the critical genes to study the
gene positioning in chemosensitive and chemoresistant ovarian cancer cell lines. The
following procedures and data demonstrated the initial steps to investigate these three main
directions (section 5.2.1, 5.2.2, and 5.2.3).
5.2.1 Isolation and characterization of nuclear associated proteins in the
chemosensitive and chemoresistant cells.
Further investigation was required to have a better understanding of the significant
differences between the chemosensitive and the chemoresistant cells that were found in
different cell-DNA substrates. Protein enzymatic digest analysis was used to study the role
of proteins involved in chemoresistant and chemosensitive ovarian cell lines.
Pellet preparation was achieved by Jesenia Perez (Florida International University, Miami,
FL, USA). Samples were delivered to the advanced mass spectrometry facility (Florida
International University, Miami, FL, USA) as white protein pellets stored in plastic
Eppendorf tubes. In-solution digestion was preformed utilizing the Thermo Scientific
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digestion kit protocol number 89895, without reduction, alkylation, or guanidination of the
proteins.
The protein enzymatic digest analysis demonstrated 522 of the total top protein found in
the samples, as shown in Figure 5.5.1. There were 327 proteins shared between
chemosensitive and chemoresistant cells. A total of 171 proteins were found in A2780,
while 24 proteins were found in SKOV3. The names and functions of these proteins were
described in Table 5.5.1, Table 5.5.2, and Table 5.5.3. Further investigations are required
to examine the protein involvement in the acquired chemoresistance. This approach will
be one of the main future directions in this study.
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Figure 5.5.1 Number of top proteins identified after mass spectrometry analysis in
the chemosensitive and chemoresistant cells.
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Table 5.5.1 Proteins shared between A2780 and SKOV3 nucleoids

Accession #

Name

Location

Function

P08670

Vimentin

nucleus, cytosol,
ER, mitochondria

P41219

Peripherin

cytosol, ECM or
secreted

P17661

Desmin

plasma membrane,
nucleus

cytoskeleton

P60709

Actin

cytosol, nucleus

cytoskeleton

P07437

Tubulin

cytosol

cytoskeleton

intermediate
filaments;
cytoskeleton
intermediate
filament (neuronal);
cytoskeleton

mito protein import
and macromol
asssembly;
facilitates correct
folding
ribosome protein
biosynthesis,
transcription factor

P10809

Heat shock protein

mitochondria

P68104

Elongation factors

plasma membrane,
nucleus

P04406

Glyceraldehyde-3phosphate
dehydrogenase
(GAPDH)

cytosol, nucleus

cytoskeleton,
nuclear functions

P06576

ATP Synthase

mitochondria

ATP production

P23528

Cofilin

nucleus, plasma
membrane, cytosol

cytoskeleton,
regulation of
morphology
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Table 5.5.2 Proteins were found only in A2780.

Accession #

Name

Q32P51

Heterogenous
nuclear
ribonucleoprotein

nucleus

P19338

Nucleolin

nucleus

P48681

Nestin

cytosol

P05387

60S acidic ribosomal
protein P2

cytosol, ECM

elongation step of
protein synthesis.

nucleus

pre-mRNA binding
proteins; p53
response;
transcription
activation and
repression

P61978

Location

Heterogeneous
nuclear
ribonucleoprotein K
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Function
package pre-mRNA,
transport poly(A)
mRNA to
cytoplasm, splice
site selection
chromatin
decondensation,
transcriptional
elongation
cytoskeleton
disassemble
vimentin
intermediate
filaments during
mitosis

Table 5.5.3 Proteins were found only in SKOV3.

Accession #

Name

Location

Function

P07355

Annexin A2

ECM

calcium-regulated
membrane binding
protein
stimulates DNA
synthesis; involved
in transcriptional
regulation of HPV
caveolae formation;
caveolae biogenesis
(required for
secretions of
protein)

P08729

Keratin, type II
cytoskeletal 7

NA

Q6NZI2

Caveolaeassociated protein 1

cytosol, ER,
nucleus,
mitochondrion

P26038

Moesin

cytosol, plasma
membrane

connects
cytoskeleton to
plasma membrane

Q8IVF2

Protein AHNAK2

nucleus

regulation of RNA
splicing
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5.2.2 Measuring cell toxicity of triazole-modified nucleosides and/or their
enhancement with cisplatin efficiency in ovarian cell line
Triazole-modified nucleosides (8-(1-H-1,2,3-triazol-4-yl)-2′-deoxyadenosine (8-TrzdA)
and 8-(1-H-1,2,3-triazol-4-yl)-2′-deoxyguanosine (8-TrzdG)) are chemical compounds
that have a fluorescent property. These compounds were obtained from Dr. Stanislaw F.
Wnuk (Florida International University, Miami, FL, USA). Using these chemical
compounds in the presence of cisplatin is reported to enhance the effectiveness of the
chemotherapy treatment. Cell toxicity of triazole-modified nucleosides was measured.
Their enhancement with cisplatin efficacy in ovarian cell lines was measured using CCK8 (section 2.2.12.2). As Figure 5.5.2 shown, using increased concentrations of the 8-TrzdG
showed no significant difference compared to the negative control. These findings illustrate
that there was no cytotoxicity was observed using this chemical compound. However,
following cisplatin treatment on the other cells group, an observed reduction was
demonstrated with all concentrations. This reduction was not significantly different from
cells, which were only treated with cisplatin, as shown in Figure 5.5.2. This result might
support the fact that this chemical compound was not able to enter the cell or did not
incorporate into DNA.
Therefore, it was important to use different methods to incorporate DNA and the chemical
compound. A2780 cells were treated with the highest concentration of 8-TrzdG (204.8
µg/mL). DNA was then isolated and divided into two groups, genomic DNA and sonicated
DNA. The reason for doing that is to demonstrate if treating cells with 8-TrzdG will
increase the size of DNA when the samples run on the gel or not. As Figure 5.5.3 shown,
there were no significant differences in the DNA size using gDNA and sonicated DNA in
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both treated and untreated samples. This implies there was not enough evidence support
that this chemical compound has incorporated into the DNA or not. Therefore, altered
methods are required to investigate the presence of 8-TrzdG in DNA samples, like HPLC.
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Figure 5.5.2 Cell viability as measured by WST-8 assay using A2780 cells after 24 h
of incubation with 8-TrzdG of different concentrations. A group of cells were also
treated with cisplatin (100 µM) for 1 h and placed after in drug-free media for 3 h. Negative
control (no 8-TrzdG/ no cisplatin), while positive control cells were treated with high
concentration of cisplatin (1 mM cisplatin), cells treated also with only cisplatin (100 µM)
and were used as a control. Data were expressed as mean ± SEM. from three experiments.
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Figure 5.5.3 Gel electrophoresis of A2780 cell line after the treatment of 8-TrzdG.
Cells were treated with 8-TrzdG (204.8 µg/mL) for 24 h, DNA was then isolated, and
samples were fragmented using sonicator for different cycle (30 sec ON/Off). DNA
samples were loaded in 1 % agarose gel. Ladder (Promega, 1 kb DNA Ladder Molecular,
Fisher).
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5.2.3 Examination changes in the DNA damage response with acquired
chemoresistance
To examine changes in the DNA damage response with acquired chemoresistance, the
chemosensitive cell line, A2780, was used to develop A2780cis in our laboratory by
chronic exposure of the parent cisplatin-sensitive A2780 cell line to increasing
concentrations of cisplatin. After six months of the chronic exposure to increasing
concentrations of cisplatin, cell viability assay (CCK8) was preformed to measure the
different between A2780 and A2780cis (section 2.2.12.1). Briefly, Cells were seeded in a
96 well plate (5000 cells/well) and incubated overnight at 37 °C, 5% CO2. Cells were then
treated with increasing concentrations of cisplatin (0.05, 0.1, 0.2, 0.4, 0.8 1.6, and 3.2 µM).
After incubation for 24 h, CCK-8 mixture (10 µL) was added to every well and the plates
were placed for 4 h at 37 °C, 5% CO2. The plate was read at 450 nm in a Biotech plate
reader (Winooski, VT, USA). There was no significant different was observed between
A2780 and A2780cis in all concentrations, (data not shown). This finding can be explained
the need of A2780CIS for more chronic exposure of cisplatin in order to acquire
chemoresistance. Therefore, we have obtained recently a commercial A2780cis (ECACC
catalogue no. 93112517). As one of the future directions, it will be important to examine
changes in the DNA damage response with acquired chemoresistance. This will play an
essential role to have a better understanding of the DNA damage response with acquired
chemoresistance.

161

5.2.4 Optimization of sonication procedure and number of cycles
As future directions also in this study, it will be essential to identify the genomic regions
associated with DNA damage and repair in chemoresistant and chemosensitive ovarian
cancer cells. This will require advance approaches like chromatin immunoprecipitation
sequencing (chip-seq) and DNA immunoprecipitation sequencing. Using these approaches,
DNA should be sheared into small fragments in the 100–300 bp range. Therefore, it was
essential to optimize the sonication step prior preforming the assay using ovarian cell lines.
Briefly, cells were treated with 100 µM of cisplatin for 1 h and then incubated in drug-free
media for 12 h. DNA was then isolated, and samples were fragmented using different
methods including Bioruptor Sonicator from Diagenode (Diagenode Inc., Sparta, NJ) (data
not shown) dsDNA fragmentase from New England Biolabs (Beverly, MA, USA) ( data
not shown), sonicator (probes) from Tekmar (Tekmar Model TM50, 50W) (Figure 5.5.4
and 5.5.5) and from Misonix (Misonix Model XL2000, 100W) (Figure 5.5.4). Depending
on the type of the procedure, different cycles were used, between (8- 60 cycles) for 15 sec
ON/Off. For the Bioruptor Sonicator, 30 sec ON/Off was used for every cycle. Afterwards,
samples were loaded in 1.5 % agarose gel.
From all the procedures that been used (data not shown), the optimum sonicator system to
shear the DNA for the ovarian cancer cell lines was the one from Tekmar (60 cycle, 15 sec
ON/Off), which produced the desired 300 bp length, as shown in Figure 5.5.4. For the other
procedures, DNA was smeared but was not at located at the desired size as showed with
using the Bioruptor Sonicator from Diagenode. Same was observed with using the
enzymatic way using dsDNA fragmentase from New England Biolabs. Using sonicator
(probes) from Misonix was the closet procedure to have DNA sheared at the desired size
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but was not showing clear bands at the desired size (300 bp) comparing to the sonicator
(probes) from Tekmar.
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Figure 5.5.4 DNA sonication of SKOV-3 using a sonicator (Probes). Cells were treated
with 100 µM of cisplatin for 1 h and then incubated in drug-free media for 12 h. DNA was
then isolated, and samples were fragmented using sonicator (probes) for different cycle (15
sec ON/Off). DNA samples were loaded in 1.5 % agarose gel. Date analysis was then
performed using ImageJ Software. Bands intensity were measured around 500-200 bp.
Two probe sonicators were used (Tekmar Model TM50, 50W) and (Misonix Model
XL2000, 100W)
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Figure 5.5.5 DNA sonication of SKOV-3 using a sonicator (Probes). Cells were treated
with 100 µM of cisplatin for 1 h and then incubated in drug-free media for 12 h. DNA was
then isolated, and samples were fragmented using sonicator (probes) for different cycle (15
sec ON/Off). DNA samples were loaded in 1.5 % agarose gel. Date analysis was then
performed using ImageJ Software. Bands intensity were measured around 500-300 bp.
Sonicator by Tekmark was used (Tekmar Model TM50, 50W).
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